Amedeo Smart

Free Medical Literature Service


 

Amedeo

Diabetes

  Free Subscription

Articles published in
Diabetes Obes Metab
    July 2021
  1. GONG L, Wang C, Ning G, Wang W, et al
    High Concentrations of Triglycerides are Associated with Diabetic Kidney Disease in New-onset Type 2 Diabetes in China: Findings from the China Cardiometabolic Disease and Cancer Cohort (4C) Study.
    Diabetes Obes Metab. 2021 Jul 28. doi: 10.1111/dom.14502.
    >> Share

  2. GOLDENBERG RM, Aroda VR, Billings LK, Christiansen ASL, et al
    Effect of Insulin Degludec versus Insulin Glargine U100 on Time in Range: SWITCH PRO, a Crossover Study of Basal Insulin-treated Adults with Type 2 Diabetes and Risk Factors for Hypoglycaemia.
    Diabetes Obes Metab. 2021 Jul 28. doi: 10.1111/dom.14504.
    >> Share

  3. KIM MN, Moon JH, Cho YM
    SGLT2 inhibition reduces cellular senescence in the diabetic kidney by promoting ketone body-induced NRF2 activation.
    Diabetes Obes Metab. 2021 Jul 28. doi: 10.1111/dom.14503.
    >> Share

  4. ELDOR R, Neutel J, Homer K, Kidron M, et al
    Efficacy and safety of 28-day treatment with oral insulin (ORMD-0801) in patients with type 2 diabetes mellitus - A randomized placebo-controlled trial.
    Diabetes Obes Metab. 2021 Jul 26. doi: 10.1111/dom.14499.
    >> Share

  5. THOMAS MG, Avari P, Godsland IF, Lett AM, et al
    Optimising type 1 diabetes after multiple daily injections and capillary blood monitoring: Pump or Sensor First? A meta-analysis using pooled differences in outcome measures.
    Diabetes Obes Metab. 2021 Jul 19. doi: 10.1111/dom.14498.
    >> Share

  6. LIU H, Sridhar VS, Montemayor D, Lovblom LE, et al
    Changes in Plasma and Urine Metabolites Associated with Empagliflozin in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2021 Jul 12. doi: 10.1111/dom.14489.
    >> Share

  7. CHERUBINI V, Rabbone I, Berioli MG, Giorda S, et al
    Effectiveness of a closed-loop control system and a virtual educational camp for children and adolescents with type 1 diabetes: a prospective multicenter real-life study.
    Diabetes Obes Metab. 2021 Jul 6. doi: 10.1111/dom.14491.
    >> Share

  8. GARDINER J, Oben J, Sutcliffe A
    Obesity as a driver of international differences in COVID-19 death rates.
    Diabetes Obes Metab. 2021;23:1463-1470.
    >> Share

  9. PATOULIAS D, Papadopoulos C, Boulmpou A, Doumas M, et al
    Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.
    Diabetes Obes Metab. 2021;23:1696-1700.
    >> Share

  10. DAHL K, Baekdal TA
    Response to the letter from Horowitz et al to the Editor relating to the publication 'Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes' by Dahl et al.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14485.
    >> Share

  11. CAMERLINGO N, Vettoretti M, Sparacino G, Facchinetti A, et al
    Design of clinical trials to assess diabetes treatments: minimal duration of CGM data to estimate time-in-ranges with a desired precision.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14483.
    >> Share

  12. BONNET F, Chen H, Cooper A, Gomes MB, et al
    What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated HbA1c (>/=7.0%) at initiation of second-line therapy? Results from the DISCOVER study.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14476.
    >> Share

  13. CLARK AL, Yan Z, Chen SX, Shi V, et al
    High fat diet prevents the development of autoimmune diabetes in NOD mice.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14486.
    >> Share

  14. GONG Q, Zhang P, Wang J, Gregg EW, et al
    Efficacy of lifestyle intervention in adults with impaired glucose tolerance with and without impaired fasting plasma glucose: a post hoc analysis of Da Qing Diabetes Prevention Outcome Study.
    Diabetes Obes Metab. 2021 Jul 1. doi: 10.1111/dom.14481.
    >> Share

  15. ARNOTT C, Li JW, Cannon CP, de Zeeuw D, et al
    The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial.
    Diabetes Obes Metab. 2021;23:1652-1659.
    >> Share

  16. MATSUBAYASHI Y, Yoshida A, Suganami H, Oe M, et al
    Association of estimated plasma volume and weight loss after long-term administration and subsequent discontinuation of the sodium-glucose cotransporter-2 inhibitor tofogliflozin.
    Diabetes Obes Metab. 2021;23:1660-1665.
    >> Share

  17. KLOECKER DE, Davies MJ, Khunti K, Zaccardi F, et al
    Cardiovascular effects of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: The P value and beyond.
    Diabetes Obes Metab. 2021;23:1685-1691.
    >> Share

  18. GHANIM H, Batra M, Green K, Hejna J, et al
    Dapagliflozin reduces systolic blood pressure and modulates vasoactive factors.
    Diabetes Obes Metab. 2021;23:1614-1623.
    >> Share

  19. BOLLI GB, Cheng A, Charbonnel B, Aroda VR, et al
    Glycaemic control and hypoglycaemia risk with insulin glargine 300 U/mL and insulin degludec 100 U/mL in older participants in the BRIGHT trial.
    Diabetes Obes Metab. 2021;23:1588-1593.
    >> Share

  20. SUISSA K, Schneeweiss S, Kim DW, Patorno E, et al
    Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the United States.
    Diabetes Obes Metab. 2021;23:1542-1551.
    >> Share

  21. PEREZ FA, Elfers C, Yanovski JA, Shoemaker AH, et al
    MRI measures of hypothalamic injury are associated with glucagon-like peptide-1 receptor agonist treatment response in people with hypothalamic obesity.
    Diabetes Obes Metab. 2021;23:1532-1541.
    >> Share

  22. VERMA S, Fainberg U, Husain M, Rasmussen S, et al
    Applying REWIND cardiovascular disease criteria to SUSTAIN 6 and PIONEER 6: An exploratory analysis of cardiovascular outcomes with semaglutide.
    Diabetes Obes Metab. 2021;23:1677-1680.
    >> Share

  23. RASSEN JA, Murk W, Schneeweiss S
    Real-world evidence of bariatric surgery and cardiovascular benefits using electronic health records data: A lesson in bias.
    Diabetes Obes Metab. 2021;23:1453-1462.
    >> Share

    June 2021
  24. BONORA E, Frias JP, Tinahones FJ, Van J, et al
    Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: Exploratory analyses of AWARD-11.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14465.
    >> Share

  25. QUAST DR, Nauck MA, Schenker N, Menge BA, et al
    Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short- and long-acting GLP-1 receptor agonists in type 2 diabetes.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14477.
    >> Share

  26. BOJER AS, Sorensen MH, Bjerre J, Gaede P, et al
    Metabolic improvement with short-term glucagon like peptide-1 receptor agonist treatment does not improve cardiac diastolic dysfunction in patients type 2 diabetes: a randomized double-blind placebo-controlled trial.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14480.
    >> Share

  27. AMADID H, Ronn PF, Dunbar MB, Knudsen JS, et al
    A large remaining potential in lipid-lowering drug treatment in the type 2 diabetes population - a Danish nationwide cohort study.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14478.
    >> Share

  28. RETNAKARAN R, Shah BR
    Impact of Pregnancy on the Trajectories of Cardiovascular Risk Factors in Women with and without Gestational Diabetes.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14479.
    >> Share

  29. CHUDASAMA YV, Zaccardi F, Coles B, Gillies CL, et al
    Ethnic, social and multimorbidity disparities in therapeutic inertia: a UK primary care observational study in patients newly diagnosed with type 2 diabetes.
    Diabetes Obes Metab. 2021 Jun 29. doi: 10.1111/dom.14482.
    >> Share

  30. POWELL RE, Zaccardi F, Beebe C, Chen XM, et al
    Strategies for overcoming therapeutic inertia in type 2 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2021 Jun 27. doi: 10.1111/dom.14455.
    >> Share

  31. HOROWITZ M, Rayner CK, Marathe CS, Wu T, et al
    Response to Dahl et al: Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
    Diabetes Obes Metab. 2021 Jun 24. doi: 10.1111/dom.14473.
    >> Share

  32. FRALICK M, Schneeweiss S, Redelmeier DA, Razak F, et al
    Comparative effectiveness and safety of SGLT2 inhibitors versus metformin in patients with type-2 diabetes: An observational study using data from routine care.
    Diabetes Obes Metab. 2021 Jun 24. doi: 10.1111/dom.14474.
    >> Share

  33. YALE JF, Catarig AM, Grau K, Harris S, et al
    Use of once-weekly semaglutide in patients with type 2 diabetes in routine clinical practice: results from the SURE Canada multicenter, prospective, observational study.
    Diabetes Obes Metab. 2021 Jun 17. doi: 10.1111/dom.14468.
    >> Share

  34. AUGUSTO GA, Cassola N, Dualib PM, Saconato H, et al
    SGLT2 inhibitors for type 2 diabetes mellitus in adults: an overview of forty-six systematic reviews.
    Diabetes Obes Metab. 2021 Jun 17. doi: 10.1111/dom.14470.
    >> Share

  35. DESHMUKH H, Wilmot EG, Gregory R, Barnes D, et al
    Predictors of Diabetes-related Distress (DRD) before and after FreeStyle Libre-1 use: Lessons from Association of British Clinical Diabetologists (ABCD) nationwide study.
    Diabetes Obes Metab. 2021 Jun 17. doi: 10.1111/dom.14467.
    >> Share

  36. YAN X, Jiang S, Lou Y, Zhou Z, et al
    Comparable efficacy and safety between LY2963016 insulin glargine and insulin glargine (Lantus(R)) in Chinese patients with type 1 diabetes: a phase III, randomized, controlled trial.
    Diabetes Obes Metab. 2021 Jun 13. doi: 10.1111/dom.14463.
    >> Share

  37. AVGERINOS I, Papanastasiou G, Karagiannis T, Michailidis T, et al
    Ultra-rapid-acting insulins for adults with diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2021 Jun 9. doi: 10.1111/dom.14461.
    >> Share

  38. NAKAMURA A, Omori K, Terauchi Y
    Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
    Diabetes Obes Metab. 2021 Jun 9. doi: 10.1111/dom.14459.
    >> Share

  39. HOCHFELLNER DA, Rainer R, Ziko H, Aberer F, et al
    Efficient and safe glycaemic control with basal-bolus insulin therapy during fasting periods in hospitalised patients with type 2 diabetes using decision support technology: a post-hoc analysis.
    Diabetes Obes Metab. 2021 Jun 3. doi: 10.1111/dom.14458.
    >> Share

  40. NASSIF ME, Windsor SL, Tang F, Husain M, et al
    Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial.
    Diabetes Obes Metab. 2021;23:1426-1430.
    >> Share

  41. SNITKER S, Andersen A, Berg B, van Marle S, et al
    Comparison of the injection-site experience of the starting doses with semaglutide and dulaglutide: A randomized, double-blind trial in healthy subjects.
    Diabetes Obes Metab. 2021;23:1415-1419.
    >> Share

  42. TOLEDO FGS, Miller RG, Helbling NL, Zhang Y, et al
    The effects of hydroxychloroquine on insulin sensitivity, insulin clearance and inflammation in insulin-resistant adults: A randomized trial.
    Diabetes Obes Metab. 2021;23:1252-1261.
    >> Share

    May 2021
  43. SHI FH, Li H, Shen L, Fu JJ, et al
    High-Dose Sodium-Glucose Co-transporter 2 Inhibitors are Superior in Type 2 Diabetes: A Meta-analysis of Randomised Clinical Trials.
    Diabetes Obes Metab. 2021 May 28. doi: 10.1111/dom.14452.
    >> Share

  44. CHAN YH, Chen SW, Chao TF, Kao YW, et al
    Impact of the initial decline in the estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 in
    Diabetes Obes Metab. 2021 May 28. doi: 10.1111/dom.14446.
    >> Share

  45. TSAPAS A, Karagiannis T, Kakotrichi P, Avgerinos I, et al
    Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis.
    Diabetes Obes Metab. 2021 May 28. doi: 10.1111/dom.14451.
    >> Share

  46. SU YC, Shao SC, Lai EC, Lee CN, et al
    Risk of Diabetic Macular Edema with Sodium Glucose Co-transporter 2 Inhibitors in Type 2 Diabetes Patients: Multi-institutional Cohort Study in Taiwan.
    Diabetes Obes Metab. 2021 May 28. doi: 10.1111/dom.14445.
    >> Share

  47. KAKU K, Kadowaki T, Seino Y, Okamoto T, et al
    Efficacy and Safety of Ipragliflozin in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control on Sitagliptin.
    Diabetes Obes Metab. 2021 May 25. doi: 10.1111/dom.14448.
    >> Share

  48. ATKIN SL, Butler AE, Hunt SC, Kilpatrick ES, et al
    The retinopathy-derived glycated hemoglobin threshold of 6.5% for type 2 diabetes also captures the risk of diabetic nephropathy in NHANES.
    Diabetes Obes Metab. 2021 May 25. doi: 10.1111/dom.14449.
    >> Share

  49. BERGET C, Akturk HK, Messer LH, Vigers T, et al
    Real world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed loop use.
    Diabetes Obes Metab. 2021 May 19. doi: 10.1111/dom.14441.
    >> Share

  50. SALARDI S, Porta M, Maltoni G, Bassi M, et al
    Decreasing Prevalence of Retinopathy in Childhood-Onset type 1 Diabetes over the Last decade. A Comparison of two Cohorts Diagnosed Ten Years Apart.
    Diabetes Obes Metab. 2021 May 17. doi: 10.1111/dom.14438.
    >> Share

  51. IDRIS I, Zhang R, Mamza JB, Ford M, et al
    Lower Risk of Hospitalisation for Heart Failure, Kidney Disease and Death with Sodium Glucose Co-Transporter-2 Compared to Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Regardless of Prior Cardiovascular or Kidney Disease: A Retrospective Cohor
    Diabetes Obes Metab. 2021 May 11. doi: 10.1111/dom.14437.
    >> Share

  52. RETNAKARAN R, Emery A, Ye C, Harris SB, et al
    Short-term Intensive Insulin as Induction and Maintenance Therapy for the Preservation of Beta-cell Function in early Type 2 Diabetes (RESET IT): A 2-year Randomized Controlled Trial.
    Diabetes Obes Metab. 2021 May 6. doi: 10.1111/dom.14421.
    >> Share

  53. DALY A, Hovorka R
    Technology in the management of type 2 diabetes - present status and future prospects.
    Diabetes Obes Metab. 2021 May 5. doi: 10.1111/dom.14418.
    >> Share

  54. QU HQ, Qu J, Bradfield J, Glessner J, et al
    Combined Application of Genetic and Polygenic Risk Score for Type 1 Diabetes Risk Prediction.
    Diabetes Obes Metab. 2021 May 5. doi: 10.1111/dom.14419.
    >> Share

  55. HE Y, Pachori A, Chen P, Ma S, et al
    Glucosuric, renal and haemodynamic effects of licogliflozin, a dual inhibitor of sodium-glucose co-transporter-1 and sodium-glucose co-transporter-2, in patients with chronic kidney disease: A randomized trial.
    Diabetes Obes Metab. 2021;23:1182-1190.
    >> Share

  56. CHILTON RJ
    Beyond the myocardium: Sodium-glucose co-transporter-2 inhibitors in heart failure.
    Diabetes Obes Metab. 2021;23:1215-1218.
    >> Share

  57. GARFIELD V, Farmaki AE, Eastwood SV, Mathur R, et al
    HbA1c and brain health across the entire glycaemic spectrum.
    Diabetes Obes Metab. 2021;23:1140-1149.
    >> Share

  58. CARIOU B, Byrne CD, Loomba R, Sanyal AJ, et al
    Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review.
    Diabetes Obes Metab. 2021;23:1069-1083.
    >> Share

  59. YAMASAKI N, Tamura Y, Kaga H, Sato M, et al
    A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin.
    Diabetes Obes Metab. 2021;23:1092-1100.
    >> Share

    April 2021
  60. KIEFER LS, Fabian J, Rospleszcz S, Lorbeer R, et al
    Distribution Patterns of Intra- and Extramyocellular Fat by Magnetic Resonance Imaging in Subjects with Diabetes, Prediabetes and Normoglycemic Controls.
    Diabetes Obes Metab. 2021 Apr 29. doi: 10.1111/dom.14413.
    >> Share

  61. WILMOT EG, Close KL, Jurisic-Erzen D, Bruttomesso D, et al
    Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: the SAGE study.
    Diabetes Obes Metab. 2021 Apr 29. doi: 10.1111/dom.14416.
    >> Share

  62. PINHO-GOMES AC, Morelli G, Jones A, Woodward M, et al
    Association of lactation with maternal risk of type 2 diabetes - a systematic review and meta-analysis of observational studies.
    Diabetes Obes Metab. 2021 Apr 28. doi: 10.1111/dom.14417.
    >> Share

  63. VAN RUITEN CC, van der Aart-van der Beek AB, IJzerman RG, Nieuwdorp M, et al
    Effect of exenatide twice daily and dapagliflozin alone and in combination on markers of kidney function in obese patients with type 2 diabetes: a prespecified secondary analysis of a randomized controlled clinical trial.
    Diabetes Obes Metab. 2021 Apr 28. doi: 10.1111/dom.14410.
    >> Share

  64. GOSMANOV AR, Gemoets DE, Kaminsky LS, Kovesdy CP, et al
    Efficacy of metformin monotherapy in US Veterans with type 2 diabetes and preexisting chronic kidney disease stage 3.
    Diabetes Obes Metab. 2021 Apr 28. doi: 10.1111/dom.14414.
    >> Share

  65. BLONDE L, Bailey T, Sullivan SD, Freemantle N, et al
    Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: a review of the DELIVER programme.
    Diabetes Obes Metab. 2021 Apr 21. doi: 10.1111/dom.14405.
    >> Share

  66. KLEIN T, Tammen H, Mark M, Benetti E, et al
    Urinary dipeptidyl peptidase-4 protein is increased by linagliptin and is a potential predictive marker of urine albumin-to-creatinine ratio reduction in patients with type 2 diabetes.
    Diabetes Obes Metab. 2021 Apr 21. doi: 10.1111/dom.14407.
    >> Share

  67. HEYWARD J, Christopher J, Sarkar S, Shin JI, et al
    AMBULATORY NON-INSULIN TREATMENT OF TYPE 2 DIABETES MELLITUS IN THE UNITED STATES, 2015-2019.
    Diabetes Obes Metab. 2021 Apr 21. doi: 10.1111/dom.14408.
    >> Share

  68. ABDELGANI S, Puckett C, Adams J, Triplitt C, et al
    Insulin Secretion is a Strong Predictor for Need of Insulin Therapy in Patients With New Onset Diabetes and HbA1c >10%, a post hoc analysis of EDICT study.
    Diabetes Obes Metab. 2021 Apr 14. doi: 10.1111/dom.14383.
    >> Share

  69. KHUNTI K, Charbonnel B, Chen H, Cherney DZ, et al
    Prevalence and progression of chronic kidney disease among patients with type 2 diabetes: insights from the DISCOVER study.
    Diabetes Obes Metab. 2021 Apr 14. doi: 10.1111/dom.14401.
    >> Share

  70. RABBONE I, Missineo A, Zanetta S, Salzano G, et al
    Parent and patient knowledge of nasal glucagon use and efficacy in a large cohort of Italian children and adolescents with type 1 diabetes.
    Diabetes Obes Metab. 2021 Apr 8. doi: 10.1111/dom.14398.
    >> Share

  71. ALEXOPOULOS AS, Andersen A, Donatsky AM, Gowda A, et al
    Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100.
    Diabetes Obes Metab. 2021 Apr 8. doi: 10.1111/dom.14397.
    >> Share

  72. SCHIAVON M, Visentin R, Gobel B, Riz M, et al
    Improved Postprandial Glucose Metabolism in Type 2 Diabetes by Dual Glucagon-like Peptide-1 / Glucagon Receptor Agonist SAR425899 in Comparison to Liraglutide.
    Diabetes Obes Metab. 2021 Apr 6. doi: 10.1111/dom.14394.
    >> Share

  73. HAYEK S, Ben-Shlomo Y, Balicer R, Byrne K, et al
    Pre-infection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study.
    Diabetes Obes Metab. 2021 Apr 6. doi: 10.1111/dom.14393.
    >> Share

  74. KOSIBOROD M, Berwanger O, Koch GG, Martinez F, et al
    Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
    Diabetes Obes Metab. 2021;23:886-896.
    >> Share

  75. KOMURO I, Kadowaki T, Bodegard J, Thuresson M, et al
    Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
    Diabetes Obes Metab. 2021;23 Suppl 2:19-27.
    >> Share

  76. KOHSAKA S, Takeda M, Kidani Y, Yajima T, et al
    Healthcare resource utilization after initiation of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors or other glucose-lowering drugs in Japanese patients with type 2 diabetes.
    Diabetes Obes Metab. 2021;23 Suppl 2:28-39.
    >> Share

  77. KOHSAKA S, Morita N, Okami S, Kidani Y, et al
    Current trends in diabetes mellitus database research in Japan.
    Diabetes Obes Metab. 2021;23 Suppl 2:3-18.
    >> Share

  78. SHAH M, Stolbov L, Yakovleva T, Tang W, et al
    A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes.
    Diabetes Obes Metab. 2021;23:991-1000.
    >> Share

  79. PATOULIAS D, Papadopoulos C, Doumas M
    Updated meta-analysis assessing the risk of amputation with sodium-glucose co-transporter-2 inhibitors in the hallmark cardiovascular and renal outcome trials.
    Diabetes Obes Metab. 2021;23:1063-1065.
    >> Share

  80. SILVERII GA, Monami M, Mannucci E
    Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2021;23:1052-1056.
    >> Share

    March 2021
  81. FENG W, Chen W, Jiang S, Du L, et al
    Efficacy and safety of LY2963016 insulin glargine versus insulin glargine (Lantus(R)) in Chinese adults with type 2 diabetes mellitus: A Phase III, randomised, open-label, controlled trial.
    Diabetes Obes Metab. 2021 Mar 30. doi: 10.1111/dom.14392.
    >> Share

  82. GONG J, Harris K, Hackett M, Peters SAE, et al
    Sex differences in risk factors for cognitive decline and dementia, including death as a competing risk, in individuals with diabetes: Results from the ADVANCE trial.
    Diabetes Obes Metab. 2021 Mar 30. doi: 10.1111/dom.14391.
    >> Share

  83. LINGVAY I, Greenberg M, Gallo S, Shi H, et al
    Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin - a VERTIS CV sub-study.
    Diabetes Obes Metab. 2021 Mar 26. doi: 10.1111/dom.14385.
    >> Share

  84. DIMOSTHENOPOULOS C, Liatis S, Kourpas E, Athanasopoulou E, et al
    The beneficial short-term effects of a high-protein/low-carbohydrate diet on glycemic control assessed by continuous glucose monitoring in patients with type 1 diabetes.
    Diabetes Obes Metab. 2021 Mar 26. doi: 10.1111/dom.14390.
    >> Share

  85. WENG J, Zeng L, Zhang Y, Qu S, et al
    Henagliflozin as add-on therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial.
    Diabetes Obes Metab. 2021 Mar 26. doi: 10.1111/dom.14389.
    >> Share

  86. D'ONOFRIO L, Pieralice S, Maddaloni E, Mignogna C, et al
    Effect of COVID-19 lockdown on glycaemic control in subjects with type 2 diabetes: the glycalock study.
    Diabetes Obes Metab. 2021 Mar 25. doi: 10.1111/dom.14380.
    >> Share

  87. BUSE JB, Holst I, Knop FK, Kvist K, et al
    Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes.
    Diabetes Obes Metab. 2021 Mar 25. doi: 10.1111/dom.14381.
    >> Share

  88. HELLGREN M, Svensson AM, Franzen S, Ericsson A, et al
    The Burden Of Poor Glycemic Control In People With Newly Diagnosed Type 2 Diabetes In Sweden: A Health Economic Modeling Analysis Based On Nationwide Data.
    Diabetes Obes Metab. 2021 Mar 17. doi: 10.1111/dom.14376.
    >> Share

  89. RUSSELL-JONES DL, Hutchison EJ, Roberts GA
    Pilots flying with insulin treated Diabetes.
    Diabetes Obes Metab. 2021 Mar 12. doi: 10.1111/dom.14375.
    >> Share

  90. GIUGLIANO D, Longo M, Caruso P, Maiorino MI, et al
    SGLT-2 inhibitors for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis.
    Diabetes Obes Metab. 2021 Mar 12. doi: 10.1111/dom.14374.
    >> Share

  91. DAHL K, Brooks A, Almazedi F, Hoff ST, et al
    Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
    Diabetes Obes Metab. 2021 Mar 12. doi: 10.1111/dom.14373.
    >> Share

  92. LIAO B, Chen Y, Chigutsa F, Piras de Oliveira C, et al
    Fasting and Postprandial Plasma Glucose Contribution to HbA1c and Time in Range in People with Type 2 Diabetes on Basal and Bolus Insulin Therapy: Results from a Pooled Analysis of Insulin Lispro Clinical Trials.
    Diabetes Obes Metab. 2021 Mar 9. doi: 10.1111/dom.14370.
    >> Share

  93. WARREN M, Bode B, Cho JI, Liu R, et al
    Improved Postprandial Glucose Control With Ultra Rapid Lispro Versus Lispro With Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes: PRONTO-Pump-2.
    Diabetes Obes Metab. 2021 Mar 9. doi: 10.1111/dom.14368.
    >> Share

  94. MOHAMMED N, Buckley A, Elsheikh M, Allum M, et al
    Bariatric surgery in the treatment of patients with obesity and type 1 diabetes - a retrospective study of clinical data.
    Diabetes Obes Metab. 2021 Mar 9. doi: 10.1111/dom.14369.
    >> Share

  95. FERREIRA JP, Lamiral Z, Bakris G, Mehta C, et al
    Red Cell Distribution Width in Patients with Diabetes and Myocardial Infarction: an analysis from the EXAMINE trial.
    Diabetes Obes Metab. 2021 Mar 9. doi: 10.1111/dom.14371.
    >> Share

  96. GOMEZ-PERALTA F, Al-Ozairi E, Jude EB, Li X, et al
    Titratable Fixed-Ratio Combination of Basal Insulin Plus a GLP-1 Receptor Agonist: A Novel, Simplified Alternative to Premix Insulin for Type 2 Diabetes.
    Diabetes Obes Metab. 2021 Mar 2. doi: 10.1111/dom.14365.
    >> Share

  97. LING JZJ, Montvida O, Khunti K, Zhang AL, et al
    Therapeutic inertia in the management of dyslipidaemia and hypertension in incident type 2 diabetes and the resulting risk factor burden: real-world evidence from primary care.
    Diabetes Obes Metab. 2021 Mar 2. doi: 10.1111/dom.14364.
    >> Share

  98. LEELARATHNA L, Choudhary P, Wilmot EG, Lumb A, et al
    Hybrid closed-loop therapy: Where are we in 2021?
    Diabetes Obes Metab. 2021;23:655-660.
    >> Share

  99. O'HARA DV, Parkhill TR, Badve SV, Jun M, et al
    The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes.
    Diabetes Obes Metab. 2021;23:763-773.
    >> Share

  100. ITO J, Nogami M, Morita Y, Sakaguchi K, et al
    Dose-dependent accumulation of glucose in the intestinal wall and lumen induced by metformin as revealed by (18) F-labelled fluorodeoxyglucose positron emission tomography-MRI.
    Diabetes Obes Metab. 2021;23:692-699.
    >> Share

    February 2021
  101. OLDGREN J, Laurila S, Akerblom A, Latva-Rasku A, et al
    Effects of 6 weeks treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes: a randomized placebo-controlled exploratory study.
    Diabetes Obes Metab. 2021 Feb 24. doi: 10.1111/dom.14363.
    >> Share

  102. ARAKI E, Mathieu C, Shiraiwa T, Maeda H, et al
    Long-term (52-week) efficacy and safety of dapagliflozin as adjunct to insulin therapy in Japanese patients with type 1 diabetes: Subgroup analysis of the DEPICT-2 study.
    Diabetes Obes Metab. 2021 Feb 23. doi: 10.1111/dom.14362.
    >> Share

  103. LI FR, Yang HL, Zhou R, Zheng JZ, et al
    Diabetes Duration and Glycemic Control as Predictors of Cardiovascular Disease and Mortality.
    Diabetes Obes Metab. 2021 Feb 23. doi: 10.1111/dom.14348.
    >> Share

  104. JUN M, Harris K, Heerspink H, Badve SV, et al
    Variability in eGFR and the risk of major clinical outcomes in diabetes: post-hoc analysis from the ADVANCE trial.
    Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14351.
    >> Share

  105. MCCRIMMON RJ, Al Sifri S, Emral R, Mohan V, et al
    Advancing therapy with iGlarLixi versus Premix 70/30 in basal insulin-treated type 2 diabetes: Design and baseline characteristics of the SoliMix randomised controlled trial.
    Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14354.
    >> Share

  106. LAM CSP, Karasik A, Melzer-Cohen C, Cavender Md MA, et al
    Association of SGLT2 inhibitors with outcomes in Type 2 diabetes with reduced and preserved left ventricular ejection fraction - Analysis from the CVD-REAL 2 Study.
    Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14356.
    >> Share

  107. BOUGHTON CK, Hartnell S, Thabit H, Poettler T, et al
    Hybrid closed-loop glucose control with faster insulin aspart (Fiasp) compared with standard insulin aspart in adults with type 1 diabetes: a double-blind, multicentre, multinational, randomised, crossover study.
    Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14355.
    >> Share

  108. BAVIERA M, Genovese S, Lepore V, Colacioppo P, et al
    Lower risk of death and cardiovascular events in patients with diabetes initiating GLP-1 receptor agonists or SGLT-2 inhibitors: a real-world study on two Italian cohorts.
    Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14361.
    >> Share

  109. TAKEUCHI Y, Kumamaru H, Hagiwara Y, Matsui H, et al
    Sodium-glucose cotransporter-2 inhibitors and the risk of urinary tract infection among diabetic patients in Japan: Target trial emulation using a nationwide administrative claims database.
    Diabetes Obes Metab. 2021 Feb 19. doi: 10.1111/dom.14353.
    >> Share

  110. PASQUEL FJ, Urrutia MA, Cardona S, Zamudio Coronado KW, et al
    Liraglutide Hospital Discharge Trial: A Randomized Controlled Trial Comparing the Safety and Efficacy of Liraglutide versus Glargine Insulin for the Management of Patients with Type 2 Diabetes After Hospital Discharge.
    Diabetes Obes Metab. 2021 Feb 16. doi: 10.1111/dom.14347.
    >> Share

  111. TIMMONS JG, Greenlaw N, Boyle JG, Chaturvedi N, et al
    Metformin and carotid intima media thickness in never smokers with type 1 diabetes: the REMOVAL trial.
    Diabetes Obes Metab. 2021 Feb 16. doi: 10.1111/dom.14350.
    >> Share

  112. MCKAY AJ, Gunn LH, Nugawela M, Sathish T, et al
    Associations between attainment of incentivised primary care indicators and incident sight-threatening diabetic retinopathy in the United Kingdom: A population-based historical cohort study.
    Diabetes Obes Metab. 2021 Feb 10. doi: 10.1111/dom.14344.
    >> Share

  113. AHMAD E, Waller HL, Sargeant JA, Webb MA, et al
    Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial.
    Diabetes Obes Metab. 2021 Feb 10. doi: 10.1111/dom.14343.
    >> Share

  114. SEINO Y, Kaku K, Kadowaki T, Okamoto T, et al
    A Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Sitagliptin in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control on Ipragliflozin.
    Diabetes Obes Metab. 2021 Feb 10. doi: 10.1111/dom.14346.
    >> Share

  115. ROSENSTOCK J, Blonde L, Aroda VR, Frias J, et al
    Switching to iGlarLixi vs Continuation of Daily or Weekly GLP-1 RA in Insufficiently Controlled Type 2 Diabetes: A LixiLan-G Trial Subgroup Analysis by HbA1c and GLP-1 RA Use at Screening.
    Diabetes Obes Metab. 2021 Feb 10. doi: 10.1111/dom.14345.
    >> Share

  116. OHKUMA T, Chalmers J, Cooper M, Hamet P, et al
    The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: results from the ADVANCE trial.
    Diabetes Obes Metab. 2021 Feb 4. doi: 10.1111/dom.14339.
    >> Share

  117. COLES B, Zaccardi F, Seidu S, Gillies CL, et al
    Rates and estimated cost of primary care consultations in people diagnosed with type 2 diabetes and comorbidities: A retrospective analysis of 8.9 million consultations.
    Diabetes Obes Metab. 2021 Feb 4. doi: 10.1111/dom.14340.
    >> Share

  118. ROUSSEL R, Darmon P, Pichelin M, Goronflot T, et al
    Use of Dipeptidyl Peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: a propensity score analysis from the CORONADO study.
    Diabetes Obes Metab. 2021 Feb 2. doi: 10.1111/dom.14324.
    >> Share

  119. HAIDAR A, Yale JF, Lovblom LE, Cardinez N, et al
    Reducing the Need for Carbohydrate Counting in Type 1 Diabetes using Closed-Loop Automated Insulin Delivery (Artificial Pancreas) and Empagliflozin: A Randomised Controlled Non-Inferiority Crossover Pilot Trial.
    Diabetes Obes Metab. 2021 Feb 2. doi: 10.1111/dom.14335.
    >> Share

  120. SIMIC A, Schondorff PK, Stumpe T, Heschel M, et al
    Survival Assessment of the Extended-Wear Insulin Infusion Set featuring Lantern Technology in Adults with Type 1 Diabetes Mellitus by Glucose Clamp Technique.
    Diabetes Obes Metab. 2021 Feb 2. doi: 10.1111/dom.14337.
    >> Share

  121. XIANG Y, Liu B, Yun C, Zhou P, et al
    Frequency, clinical features, inflammatory cytokines and genetic background of latent autoimmune diabetes in youth in youth-onset type 2 diabetes (LADA China study): a nationwide, multicenter, clinic-based cross-sectional study.
    Diabetes Obes Metab. 2021 Feb 2. doi: 10.1111/dom.14336.
    >> Share

  122. SARMA S, Sockalingam S, Dash S
    Obesity as a multisystem disease: Trends in obesity rates and obesity-related complications.
    Diabetes Obes Metab. 2021;23 Suppl 1:3-16.
    >> Share

  123. POTTEGARD A, Lund LC, Henriksen DP, Folkestad L, et al
    Use of dipeptidyl peptidase-4 inhibitors and risk of splanchnic vein thrombosis: A Danish nationwide new-user active comparator cohort study.
    Diabetes Obes Metab. 2021;23:648-652.
    >> Share

  124. KOOMEN JV, Stevens J, Bakris G, Correa-Rotter R, et al
    Inter-individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial.
    Diabetes Obes Metab. 2021;23:561-568.
    >> Share

  125. CLEMMENSEN KKB, Blond MB, Amadid H, Bruhn L, et al
    No effects of dapagliflozin, metformin or exercise on plasma glucagon concentrations in individuals with prediabetes: A post hoc analysis from the randomized controlled PRE-D trial.
    Diabetes Obes Metab. 2021;23:530-539.
    >> Share

  126. KOH ES, Han K, Nam YS, Wittbrodt ET, et al
    Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea).
    Diabetes Obes Metab. 2021;23:455-466.
    >> Share

  127. SUN JW, Hernandez-Diaz S, Bourgeois FT, Haneuse S, et al
    Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019.
    Diabetes Obes Metab. 2021;23:444-454.
    >> Share

  128. NEUEN BL, Arnott C, Perkovic V, Figtree G, et al
    Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes.
    Diabetes Obes Metab. 2021;23:382-390.
    >> Share

  129. ROTH CL, Perez FA, Whitlock KB, Elfers C, et al
    A phase 3 randomized clinical trial using a once-weekly glucagon-like peptide-1 receptor agonist in adolescents and young adults with hypothalamic obesity.
    Diabetes Obes Metab. 2021;23:363-373.
    >> Share

  130. GERSTEIN HC, Branch K, Heenan L, Del Prato S, et al
    Design and baseline characteristics of the AMPLITUDE-O cardiovascular outcomes trial of efpeglenatide, a weekly glucagon-like peptide-1 receptor agonist.
    Diabetes Obes Metab. 2021;23:318-323.
    >> Share

    January 2021
  131. KADOWAKI T, Seino Y, Kaku K, Okamoto T, et al
    A Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adding Omarigliptin to Insulin Therapy in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.
    Diabetes Obes Metab. 2021 Jan 29. doi: 10.1111/dom.14331.
    >> Share

  132. VERMA S, Mazer CD, Inzucchi SE, Wanner C, et al
    Impact of polyvascular disease with and without coexistent kidney dysfunction on cardiovascular outcomes in diabetes: a post-hoc analysis of EMPA-REG OUTCOME(R).
    Diabetes Obes Metab. 2021 Jan 27. doi: 10.1111/dom.14326.
    >> Share

  133. TASKINEN MR, Bjornson E, Matikainen N, Soderlund S, et al
    Effects of liraglutide on the metabolism of triglyceride-rich lipoproteins in type 2 diabetes.
    Diabetes Obes Metab. 2021 Jan 27. doi: 10.1111/dom.14328.
    >> Share

  134. BASTRUP ISRAELSEN S, Pottegard A, Sandholdt H, Madsbad S, et al
    Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2.
    Diabetes Obes Metab. 2021 Jan 27. doi: 10.1111/dom.14329.
    >> Share

  135. PARK SH, Jeong HE, Oh IS, Hong SM, et al
    Cardiovascular safety of evogliptin in patients with type 2 diabetes mellitus: a nationwide cohort study.
    Diabetes Obes Metab. 2021 Jan 27. doi: 10.1111/dom.14330.
    >> Share

  136. LING J, Koye D, Buizen L, Khunti K, et al
    Temporal Trends in Comorbidities and Cardiometabolic Risk Factors at the Time of Diagnosis of Type 2 Diabetes in UK.
    Diabetes Obes Metab. 2021 Jan 26. doi: 10.1111/dom.14323.
    >> Share

  137. BAE J, Song KH, Park JS, Lee JH, et al
    Safety and effectiveness of sean patients with type 2 diabetes mellitus: A post-marketing surveillance study.
    Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14317.
    >> Share

  138. OSHIRO A, Ohkuma T, Sakamoto W, Komorita Y, et al
    An adult patient with permanent neonatal diabetes successfully discontinued insulin therapy after initiating sitagliptin added to sulphonylurea.
    Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14318.
    >> Share

  139. HARREITER J, Just I, Leutner M, Bastian M, et al
    Combined EXENatide and DApagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycemic control in patients with type 2 diabetes mellitus treated with metformin -EXENDA, a 24 week, prospective, randomized, placebo-co
    Diabetes Obes Metab. 2021 Jan 19. doi: 10.1111/dom.14319.
    >> Share

  140. LU J, Fu L, Li Y, Geng J, et al
    Henagliflozin Monotherapy in Patients with Type 2 Diabetes Inadequately Controlled on Diet and Exercise: A Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
    Diabetes Obes Metab. 2021 Jan 8. doi: 10.1111/dom.14314.
    >> Share

  141. BUDHRAM D, Benipal S, Bilimoria K, Maraj D, et al
    Essential Diabetes Medicines and Health Outcomes in 127 Countries.
    Diabetes Obes Metab. 2021 Jan 8. doi: 10.1111/dom.14316.
    >> Share

  142. KITAZAWA M, Katagiri T, Suzuki H, Matsunaga S, et al
    A 52-week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N-ISM study.
    Diabetes Obes Metab. 2021 Jan 8. doi: 10.1111/dom.14288.
    >> Share

  143. LEE M, Kim KJ, Chung TH, Bae J, et al
    Non-alcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetes.
    Diabetes Obes Metab. 2021 Jan 4. doi: 10.1111/dom.14310.
    >> Share

  144. RAGHAVAN S, Jablonski K, Delahanty LM, Maruthur NM, et al
    Interaction of diabetes genetic risk and successful lifestyle modification in the Diabetes Prevention Program.
    Diabetes Obes Metab. 2021 Jan 4. doi: 10.1111/dom.14309.
    >> Share

  145. CLEGG LE, Jing Y, Penland RC, Boulton DW, et al
    Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: observations from the EXSCEL and SAVOR-TIMI 53 cardiovascular outcomes trials.
    Diabetes Obes Metab. 2021 Jan 4. doi: 10.1111/dom.14313.
    >> Share

  146. SAINSBURY C, Wang J, Gokhale K, Acosta-Mena D, et al
    Sodium-glucose co-transporter-2 inhibitors and susceptibility to COVID-19: A population-based retrospective cohort study.
    Diabetes Obes Metab. 2021;23:263-269.
    >> Share

  147. MASHAYEKHI M, Wilson JR, Jafarian-Kerman S, Nian H, et al
    Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal.
    Diabetes Obes Metab. 2021;23:281-286.
    >> Share

  148. WERNER U, Tennagels N, Fanelli CG, Bolli GB, et al
    Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.
    Diabetes Obes Metab. 2021;23:166-174.
    >> Share

  149. OKUNRINTEMI V, Mishriky BM, Powell JR, Cummings DM, et al
    Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials.
    Diabetes Obes Metab. 2021;23:276-280.
    >> Share

  150. GUENSCH DP, Tripyla A, Fischer K, Vogt AP, et al
    First insights into the performance of the Dexcom G6 continuous glucose monitoring system during cardiac surgery using hypothermic extracorporal circulation.
    Diabetes Obes Metab. 2021;23:294-295.
    >> Share

  151. HAMEED S, Salem V, Alessimii H, Scholtz S, et al
    Imperial Satiety Protocol: A new non-surgical weight-loss programme, delivered in a health care setting, produces improved clinical outcomes for people with obesity.
    Diabetes Obes Metab. 2021;23:270-275.
    >> Share

  152. DANDONA P, Dhindsa S, Ghanim H, Saad F, et al
    Mechanisms underlying the metabolic actions of testosterone in humans: A narrative review.
    Diabetes Obes Metab. 2021;23:18-28.
    >> Share

  153. SALAHUDDIN T, Richardson V, McNeal DM, Henderson K, et al
    Potential unrealized mortality benefit of glucagon-like peptide-1 receptor agonists and sodium-glucose co-transport-2 inhibitors: A report from the Veterans Health Administration Clinical Assessment, Reporting and Tracking program.
    Diabetes Obes Metab. 2021;23:97-105.
    >> Share

  154. CAHN A, Wiviott SD, Mosenzon O, Murphy SA, et al
    Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.
    Diabetes Obes Metab. 2021;23:29-38.
    >> Share

    December 2020
  155. PAGANO E, Konings SR, Di Cuonzo D, Rosato R, et al
    Prediction of mortality and major cardiovascular complications in type 2 diabetes: external validation of UKPDS outcomes model version 2 in two European observational cohorts.
    Diabetes Obes Metab. 2020 Dec 29. doi: 10.1111/dom.14311.
    >> Share

  156. MCEWAN P, Morgan AR, Boyce R, Bergenheim K, et al
    The cost-effectiveness of dapagliflozin in treating high risk patients with type 2 diabetes mellitus: an economic evaluation using data from the DECLARE-TIMI 58 trial.
    Diabetes Obes Metab. 2020 Dec 28. doi: 10.1111/dom.14308.
    >> Share

  157. MILLER EG, Nowson CA, Dunstan DW, Kerr DA, et al
    Effects of whey protein plus vitamin D supplementation combined with resistance training on glycemic control, body composition, muscle function and cardiometabolic risk factors in middle-aged and older overweight/obese adults with type 2 diabetes? A 2
    Diabetes Obes Metab. 2020 Dec 23. doi: 10.1111/dom.14299.
    >> Share

  158. FRALICK M, Colacci M, Thiruchelvam D, Gomes T, et al
    SGLT2 inhibitors versus DPP4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus.
    Diabetes Obes Metab. 2020 Dec 18. doi: 10.1111/dom.14300.
    >> Share

  159. LAUGESEN C, Schmidt S, Holst JJ, Norgaard K, et al
    The Effect of Preceding Glucose Decline Rate on Low-Dose Glucagon Efficacy in Individuals with Type 1 Diabetes: A Randomized Cross-Over Trial.
    Diabetes Obes Metab. 2020 Dec 18. doi: 10.1111/dom.14301.
    >> Share

  160. LAZAR NETO F, Mendes TB, Matos PMPG, de Oliveira JC, et al
    External Validity of Type 2 Diabetes Clinical Trials on Cardiovascular Outcomes for a Multimorbid Population.
    Diabetes Obes Metab. 2020 Dec 18. doi: 10.1111/dom.14303.
    >> Share

  161. ANDERSEN G, Meiffren G, Famulla S, Heise T, et al
    ADO09, a co-formulation of the amylin-analog pramlintide and the insulin analog A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes (T1D).
    Diabetes Obes Metab. 2020 Dec 18. doi: 10.1111/dom.14302.
    >> Share

  162. RAPATTONI W, Zante D, Tomas M, Myageri V, et al
    A retrospective observational population-based study to assess the prevalence and burden of illness of type 2 diabetes with eGFR <90ml/min/1.73m(2) in Ontario, Canada.
    Diabetes Obes Metab. 2020 Dec 15. doi: 10.1111/dom.14294.
    >> Share

  163. BELL D, Goncalves E
    Diabetogenic effects of cardioprotective drugs.
    Diabetes Obes Metab. 2020 Dec 15. doi: 10.1111/dom.14295.
    >> Share

  164. DONG W, Wan YFE, Fong YTD, Kwok LPR, et al
    Prediction Models and Nomograms of 10-year Risk of End-Stage Renal Disease in Chinese Type 2 Diabetes Mellitus Patients in Primary Care.
    Diabetes Obes Metab. 2020 Dec 15. doi: 10.1111/dom.14292.
    >> Share

  165. JACOB L, Rickwood S, Rathmann W, Kostev K, et al
    Change in glucose-lowering medication regimen in individuals with type 2 diabetes mellitus during the COVID-19 pandemic in Germany.
    Diabetes Obes Metab. 2020 Dec 15. doi: 10.1111/dom.14293.
    >> Share

  166. JUDE EB, Trescoli C, Emral R, Ali A, et al
    Effectiveness of premixed insulin to achieve glycaemic control in type 2 diabetes: a retrospective UK cohort study.
    Diabetes Obes Metab. 2020 Dec 15. doi: 10.1111/dom.14298.
    >> Share

  167. AVGERINOS I, Manolopoulos A, Michailidis T, Kitsios K, et al
    Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: a systematic review and network meta-analysis.
    Diabetes Obes Metab. 2020 Dec 10. doi: 10.1111/dom.14291.
    >> Share

  168. ECKSTEIN ML, Moser O, Tripolt NJ, Pferschy PN, et al
    Rapid glucose rise reduces heart rate variability in adults with type 1 diabetes- a prospective secondary outcome analysis.
    Diabetes Obes Metab. 2020 Dec 7. doi: 10.1111/dom.14287.
    >> Share

  169. DUBOURG J, Ueki K, Grouin JM, Fouqueray P, et al
    Efficacy And Safety Of Imeglimin In Japanese Patients With Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2b Trial.
    Diabetes Obes Metab. 2020 Dec 4. doi: 10.1111/dom.14285.
    >> Share

  170. HALLAKOU-BOZEC S, Vial G, Kergoat M, Fouqueray P, et al
    Mechanism Of Action Of Imeglimin - A Novel Therapeutic Agent For Type 2 Diabetes.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14277.
    >> Share

  171. STRELITZ J, Sharp SJ, Khunti K, Vos RC, et al
    Association of weight loss and weight loss maintenance following diabetes diagnosis by screening and incidence of cardiovascular disease and all-cause mortality: an observational analysis of the ADDITION-Europe trial.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14278.
    >> Share

  172. ELHARRAM M, Ferreira JP, Huynh T, Ni J, et al
    Prediction of Heart Failure Outcomes in Patients with Type 2 Diabetes Mellitus: Validation of the TRS-HFDM Score in the ACCORD Trial.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14283.
    >> Share

  173. LIU W, Chen J, He L, Cai X, et al
    Flash Glucose Monitoring Data Analyzed by Detrended Fluctuation Function on beta Cell Function and Diabetes Classification.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14282.
    >> Share

  174. HUANG YM, Lin YK, Lee WJ, Hur KY, et al
    Long-term Outcomes of Metabolic Surgery in Overweight and Obese Patients with Type 2 Diabetes Mellitus in Asia.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14279.
    >> Share

  175. DANNE T, Edelman S, Frias JP, Ampudia-Blasco FJ, et al
    Efficacy and safety of adding sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline BMI >/=27 kg/m(2).
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14271.
    >> Share

  176. SVENSSON AM, Toll A, Lebrec J, Miftaraj M, et al
    Treatment persistence in patients with type 2 diabetes mellitus treated with GLP-1 receptor agonists in clinical practice in Sweden.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14276.
    >> Share

  177. THOM G, McIntosh A, Messow CM, Leslie WS, et al
    Weight loss induced increase in fasting ghrelin concentration is a predictor of weight regain: evidence from the Diabetes Remission Clinical Trial.
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14274.
    >> Share

  178. THOM G, McIntosh A, Messow CM, Leslie WS, et al
    Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: Evidence from the Diabetes Remission Clinical Trial (DiRECT).
    Diabetes Obes Metab. 2020 Dec 2. doi: 10.1111/dom.14274.
    >> Share

  179. ALI N, Janssen AWM, Jaeger M, Van de Wijer L, et al
    Limited impact of impaired awareness of hypoglycaemia and severe hypoglycaemia on the inflammatory profile of people with type 1 diabetes.
    Diabetes Obes Metab. 2020;22:2427-2436.
    >> Share

  180. WILSON JM, Nikooienejad A, Robins DA, Roell WC, et al
    The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020;22:2451-2459.
    >> Share

    November 2020
  181. KING AB
    The Mean Basal Insulin Dose is 0.2 U/kg/d At Near Normal Glycemia for Type 1 or 2 Diabetes on Continuous Subcutaneous Insulin Infusion or Once-Nightly Basal Insulin.
    Diabetes Obes Metab. 2020 Nov 27. doi: 10.1111/dom.14265.
    >> Share

  182. SATHISH T, Kapoor N, Cao Y, Tapp RJ, et al
    Proportion of newly diagnosed diabetes in COVID-19 patients: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2020 Nov 27. doi: 10.1111/dom.14269.
    >> Share

  183. KAPITZA C, Nosek L, Schmider W, Teichert L, et al
    Single-dose euglycemic clamp study in two cohorts to compare exposure of SAR341402 (insulin aspart) Mix 70/30 to US- and EU-Approved versions of insulin aspart Mix 70/30 and SAR341402 rapid-acting solution in subjects with type 1 diabetes.
    Diabetes Obes Metab. 2020 Nov 25. doi: 10.1111/dom.14260.
    >> Share

  184. HAN SJ, Ha KH, Lee N, Kim DJ, et al
    Effectiveness and safety of SGLT2 inhibitors compared to dipeptidyl peptidase (DPP)-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
    Diabetes Obes Metab. 2020 Nov 25. doi: 10.1111/dom.14261.
    >> Share

  185. TOMMERDAHL KL, Bjornstad P, Kendrick J, Cree-Green M, et al
    Results from the Effects of MEtformin on CardiovasculaR Function in AdoLescents with Type 1 Diabetes (EMERALD) Study: A Brief Report of Kidney and Inflammatory Outcomes.
    Diabetes Obes Metab. 2020 Nov 25. doi: 10.1111/dom.14266.
    >> Share

  186. REIFSNIDER O, Kansal A, Pimple P, Aponte-Ribero V, et al
    Cost-effectiveness Analysis of Empagliflozin versus Sitagliptin as Second-Line Therapy for Treatment in Patients with Type 2 Diabetes in the United States.
    Diabetes Obes Metab. 2020 Nov 25. doi: 10.1111/dom.14268.
    >> Share

  187. KOMORIZONO Y, Hosoyamada K, Imamura N, Kajiya S, et al
    Metformin increase versus added linagliptin in nonalcoholic liver disease and type 2 diabetes: An analysis of J-LINK study.
    Diabetes Obes Metab. 2020 Nov 25. doi: 10.1111/dom.14263.
    >> Share

  188. MAURICIO D, Westerbacka J, Nicholls C, Wu J, et al
    How many people with type 2 diabetes fulfil eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?
    Diabetes Obes Metab. 2020 Nov 25. doi: 10.1111/dom.14264.
    >> Share

  189. BIESTER T, Muller I, dem Berge T, Atlas E, et al
    Add-on Therapy with Dapagliflozin under Full Closed Loop Control improves Time in Range in Adolescents and young Adults with Type 1 Diabetes- The DAPADream Study.
    Diabetes Obes Metab. 2020 Nov 20. doi: 10.1111/dom.14258.
    >> Share

  190. BAE J, Huh JH, Lee M, Lee YH, et al
    Glycemic control with add-on thiazolidinedione or sodium glucose co-transporter 2 inhibitor in type 2 diabetes mellitus patients after failure of an oral triple antidiabetic regimen: A 24-week randomized controlled trial.
    Diabetes Obes Metab. 2020 Nov 20. doi: 10.1111/dom.14259.
    >> Share

  191. SOURIJ H, Aziz F, Brauer A, Ciardi C, et al
    Covid-19 fatality prediction in people with diabetes and prediabetes using a simple score at hospital admission.
    Diabetes Obes Metab. 2020 Nov 16. doi: 10.1111/dom.14256.
    >> Share

  192. OLAFSDOTTIR AF, Bolinder J, Heise T, Polonsky W, et al
    Majority of people with type 1 diabetes and multiple daily insulin injection benefit by using Continuous Glucose Monitoring: An analysis based on the GOLD randomised trial (GOLD-5).
    Diabetes Obes Metab. 2020 Nov 16. doi: 10.1111/dom.14257.
    >> Share

  193. ESPELAND MA, Pratley RE, Rosenstock J, Kadowaki T, et al
    Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: a subgroup analysis of the randomized CAROLINA trial.
    Diabetes Obes Metab. 2020 Nov 12. doi: 10.1111/dom.14254.
    >> Share

  194. GIBBONS C, Blundell J, Hoff ST, Dahl K, et al
    Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes.
    Diabetes Obes Metab. 2020 Nov 12. doi: 10.1111/dom.14255.
    >> Share

  195. KHOO CM, Deerochanawong C, Siew Pheng C, Matawaran B, et al
    Use of sodium glucose cotransporter-2 inhibitors in Asian patients with type 2 diabetes mellitus and kidney disease: An Asian perspective and expert recommendations.
    Diabetes Obes Metab. 2020 Nov 6. doi: 10.1111/dom.14251.
    >> Share

  196. SHANG W, Zhang Y, Wang G, Han D, et al
    Benefits of CPAP on glycemic control and insulin resistance in patients with type 2 diabetes and obstructive sleep apnea: a meta-analysis.
    Diabetes Obes Metab. 2020 Nov 4. doi: 10.1111/dom.14247.
    >> Share

  197. PHILLIP M, Mathieu C, Lind M, Araki E, et al
    Long-Term Efficacy and Safety of Dapagliflozin in Patients with Inadequately Controlled Type 1 Diabetes: Pooled 52-Week Outcomes from the DEPICT-1 and -2 Studies.
    Diabetes Obes Metab. 2020 Nov 4. doi: 10.1111/dom.14248.
    >> Share

  198. FUNCK KL, Knudsen JS, Krarup Hansen T, Thomsen RW, et al
    Real-world use of cardioprotective glucose-lowering drugs in patients with type 2 diabetes and cardiovascular disease: A Danish nationwide cohort study 2012-2019.
    Diabetes Obes Metab. 2020 Nov 2. doi: 10.1111/dom.14245.
    >> Share

  199. BOYE K, Ross M, Mody R, Konig M, et al
    Patients' Preferences for Once-Daily Oral Versus Once-Weekly Injectable Diabetes Medications: The REVISE Study.
    Diabetes Obes Metab. 2020 Nov 2. doi: 10.1111/dom.14244.
    >> Share

  200. CARDONA S, Tsegka K, Pasquel FJ, Jacobs S, et al
    Sitagliptin for the Prevention and Treatment of Perioperative Hyperglycaemia in Patients with Type 2 Diabetes Undergoing Cardiac Surgery: A Randomised Controlled Trial.
    Diabetes Obes Metab. 2020 Nov 2. doi: 10.1111/dom.14241.
    >> Share

  201. HUANG HK, Liu PP, Lin SM, Hsu JY, et al
    Risk of Developing Diabetes Mellitus in Patients with Atrial Fibrillation Taking Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin: A Nationwide Cohort Study.
    Diabetes Obes Metab. 2020 Nov 2. doi: 10.1111/dom.14243.
    >> Share

    October 2020
  202. LIU CS, Li CI, Wang MC, Yang SY, et al
    Building clinical risk score systems for predicting the all-cause and expanded cardiovascular-specific mortality of patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Oct 29. doi: 10.1111/dom.14240.
    >> Share

  203. PETERS A, Cohen N, Calhoun P, Ruedy K, et al
    Glycemic profiles of diverse patients with type 2 diabetes using basal insulin: MOBILE study baseline data.
    Diabetes Obes Metab. 2020 Oct 29. doi: 10.1111/dom.14238.
    >> Share

  204. ANTAKLY HANON Y, Ben Hamou A, Garcon P, Moeuf Y, et al
    Asymptomatic left ventricular dysfunction in type 2 diabetic patients free of cardio vascular disease and relationship with clinical characteristics: The DIACAR cohort study.
    Diabetes Obes Metab. 2020 Oct 29. doi: 10.1111/dom.14236.
    >> Share

  205. INZUCCHI SE, Davies MJ, Khunti K, Trivedi P, et al
    Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Oct 20. doi: 10.1111/dom.14234.
    >> Share

  206. YANG W, Xu X, Lei T, Ma J, et al
    Efficacy and safety of linagliptin as add-on therapy to insulin in Chinese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2020 Oct 19. doi: 10.1111/dom.14231.
    >> Share

  207. JI L, Dong X, Li Y, Li Y, et al
    Efficacy and safety of once-weekly semaglutide vs once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes (SUSTAIN China): a 30-week double-blind, phase 3a, randomised trial.
    Diabetes Obes Metab. 2020 Oct 19. doi: 10.1111/dom.14232.
    >> Share

  208. SMATI S, Tramunt B, Wargny M, Caussy C, et al
    Relationship between obesity and severe COVID-19 outcomes in patients with type 2 diabetes: results from the CORONADO study.
    Diabetes Obes Metab. 2020 Oct 14. doi: 10.1111/dom.14228.
    >> Share

  209. JOUBERT M, Opigez V, Pavlikova B, Paul LPS, et al
    Efficacy and safety of Exenatide as add-on therapy for type 2 diabetes patients with intensive insulin regimen: a randomized double-blind trial.
    Diabetes Obes Metab. 2020 Oct 12. doi: 10.1111/dom.14225.
    >> Share

  210. COLES B, Zaccardi F, Hvid C, Davies MJ, et al
    Cardiovascular events and mortality in people with type 2 diabetes and multimorbidity: a real world study of patients followed up to 19 years.
    Diabetes Obes Metab. 2020 Oct 7. doi: 10.1111/dom.14218.
    >> Share

  211. RABEN A, Vestentoft PS, Brand-Miller J, Jalo E, et al
    PREVIEW - Results from a 3-year randomised 2 x 2 factorial multinational trial investigating the role of protein, glycemic index and physical activity for prevention of type-2 diabetes.
    Diabetes Obes Metab. 2020 Oct 7. doi: 10.1111/dom.14219.
    >> Share

  212. TANDON S, Ayis S, Hopkins D, Harding S, et al
    The impact of pharmacological and lifestyle interventions on body weight in people with type 1 diabetes: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2020 Oct 7. doi: 10.1111/dom.14221.
    >> Share

  213. MOIN ASM, Al-Qaissi A, Sathyapalan T, Atkin SL, et al
    Hypoglycemia in Type 2 Diabetes exacerbates Amyloid-related proteins associated with dementia.
    Diabetes Obes Metab. 2020 Oct 7. doi: 10.1111/dom.14220.
    >> Share

  214. PHAM TT, Wetzel O, Gariani K, Kressmann B, et al
    Is Routine Measurement of the Serum C-Reactive Protein Level Helpful During Antibiotic Therapy for Diabetic Foot Infection?
    Diabetes Obes Metab. 2020 Oct 7. doi: 10.1111/dom.14222.
    >> Share

  215. LI D, Zou HJ, Yin P, Li W, et al
    Durability of Glycaemic Control in Type 2 Diabetes: A Systematic Review and Meta-analysis for its Association with Body Weight Changes.
    Diabetes Obes Metab. 2020 Oct 5. doi: 10.1111/dom.14217.
    >> Share

  216. BENHAMOU PY, Lablanche S, Vambergue A, Doron M, et al
    Highly unstable type 1 diabetes eligible for islet transplantation can be managed with closed-loop insulin delivery. A series of N-of-1 randomised controlled trials.
    Diabetes Obes Metab. 2020 Oct 1. doi: 10.1111/dom.14214.
    >> Share

  217. SINGH AK, Gillies CL, Singh R, Singh A, et al
    Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2020;22:1915-1924.
    >> Share

  218. LI J, Wang X, Chen J, Zuo X, et al
    COVID-19 infection may cause ketosis and ketoacidosis.
    Diabetes Obes Metab. 2020;22:1935-1941.
    >> Share

    September 2020
  219. HELLER S, Lingvay I, Marso SP, Philis-Tsimikas A, et al
    Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE.
    Diabetes Obes Metab. 2020 Sep 30. doi: 10.1111/dom.14208.
    >> Share

  220. JI L, Chan JC, Yu M, Yoon KH, et al
    Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes mellitus - an East Asian perspective.
    Diabetes Obes Metab. 2020 Sep 29. doi: 10.1111/dom.14205.
    >> Share

  221. HANSEN GM, Jorgensen PG, Andersen HU, Rossing P, et al
    Relationship between Peripheral Neuropathy, Diastolic Function, and Adverse Cardiovascular Outcome in Individuals with Type 1 Diabetes Mellitus without Known Cardiovascular Disease: Results from The Thousand & 1 Study.
    Diabetes Obes Metab. 2020 Sep 29. doi: 10.1111/dom.14209.
    >> Share

  222. RAYNER CK, Wu T, Aroda VR, Whittington C, et al
    Gastrointestinal adverse events with insulin glargine/lixisenatide fixed-ratio combination versus GLP-1 RAs in people with type 2 diabetes mellitus: a network meta-analysis.
    Diabetes Obes Metab. 2020 Sep 29. doi: 10.1111/dom.14202.
    >> Share

  223. SHUAI Y, Yang G, Zhang Q, Li W, et al
    Efficacy and safety of polyethylene glycol loxenatide (PEX168) monotherapy in type 2 diabetes patients: a multicenter, randomized, double-blind, placebo-controlled, phase 3a clinical trial.
    Diabetes Obes Metab. 2020 Sep 23. doi: 10.1111/dom.14198.
    >> Share

  224. SHEN Y, Zhou J, Shi L, Nauman E, et al
    Association between visit-to-visit hemoglobin A1c variability and the risk of cardiovascular disease in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Sep 23. doi: 10.1111/dom.14201.
    >> Share

  225. LI C, Zhou Z, Neuen BL, Yu J, et al
    Sodium-Glucose Co-transporter-2 Inhibition and ocular outcomes in patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
    Diabetes Obes Metab. 2020 Sep 21. doi: 10.1111/dom.14197.
    >> Share

  226. MODY R, Yu M, Nepal B, Konig M, et al
    Adherence and Persistence among Patients with Type 2 Diabetes Initiating Dulaglutide compared with Semaglutide and Exenatide BCise: 6-month Follow-up from US Real-World Data.
    Diabetes Obes Metab. 2020 Sep 18. doi: 10.1111/dom.14195.
    >> Share

  227. HERZIG D, Studer D, Nakas CT, Kuenzli C, et al
    Effect of fully automated closed-loop insulin delivery using faster aspart versus standard aspart on gluco-regulatory hormones in type 2 diabetes.
    Diabetes Obes Metab. 2020 Sep 9. doi: 10.1111/dom.14185.
    >> Share

  228. CHAN JC, Paldanius PM, Mathieu C, Stumvoll M, et al
    Early combination therapy delayed treatment escalation in newly-diagnosed young-onset type 2 diabetes - a sub-analysis of VERIFY study.
    Diabetes Obes Metab. 2020 Sep 7. doi: 10.1111/dom.14192.
    >> Share

  229. SUGAMA J, Katayama Y, Moritoh Y, Watanabe M, et al
    Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease.
    Diabetes Obes Metab. 2020 Sep 7. doi: 10.1111/dom.14190.
    >> Share

  230. BIRKELAND KI, Bodegard J, Banerjee A, Kim DJ, et al
    Lower Cardiorenal Risk with Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Patients without Cardiovascular and Renal Diseases: A large multinational observational study.
    Diabetes Obes Metab. 2020 Sep 7. doi: 10.1111/dom.14189.
    >> Share

  231. CHEN J, Fan L, Peng X, Ilag L, et al
    Patient-Reported Outcomes in a Study of Human Regular U-500 Insulin Delivered by Continuous Subcutaneous Insulin Infusion or Multiple Daily Injections in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2020 Sep 7. doi: 10.1111/dom.14191.
    >> Share

  232. BANHOLZER N, Herzig D, Piazza C, Alvarez Martinez M, et al
    Effect of nutrition on postprandial glucose control in hospitalized patients with type 2 diabetes receiving fully automated closed-loop insulin therapy.
    Diabetes Obes Metab. 2020 Sep 4. doi: 10.1111/dom.14187.
    >> Share

  233. ANDERSEN IB, Andreassen M, Krogh J
    The effect of dopamine agonists on metabolic variables in adults with type 2 diabetes. A systematic review with meta-analysis and trial sequential analysis of randomized clinical trials.
    Diabetes Obes Metab. 2020 Sep 1. doi: 10.1111/dom.14183.
    >> Share

  234. TERAUCHI Y, Yabe D, Kaneto H, Amano A, et al
    Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Diabetes Obes Metab. 2020;22 Suppl 4:35-47.
    >> Share

    August 2020
  235. PATEL KK, Gomes MB, Charbonnel B, Chen H, et al
    Global Patterns of Comprehensive Cardiovascular Risk Factor Control in Patients with Type 2 Diabetes Mellitus: Insights from the DISCOVER Study.
    Diabetes Obes Metab. 2020 Aug 26. doi: 10.1111/dom.14180.
    >> Share

  236. BELUR NAGARAJ S, Pena MJ, Ju W, Heerspink HL, et al
    Machine Learning based Early Prediction of End-stage Renal Disease in Patients with Diabetic Kidney Disease using Clinical Trials Data.
    Diabetes Obes Metab. 2020 Aug 26. doi: 10.1111/dom.14178.
    >> Share

  237. TANDAY N, Irwin N, Moffett RC, Flatt PR, et al
    Beneficial actions of a long-acting apelin analogue in diabetes are related to positive effects on islet cell turnover and transdifferentiation.
    Diabetes Obes Metab. 2020 Aug 26. doi: 10.1111/dom.14177.
    >> Share

  238. GENTILE S, Strollo F, Mambro A, Ceriello A, et al
    COVID-19, ketoacidosis, and new-onset Diabetes: might we envisage any cause-effect relationships among them?
    Diabetes Obes Metab. 2020 Aug 13. doi: 10.1111/dom.14170.
    >> Share

  239. ZACCARDI F, Jacquot E, Cortese V, Tyrer F, et al
    Comparative effectiveness of gliclazide modified release vs sitagliptin as second-line treatment after metformin monotherapy in patients with uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2020 Aug 5. doi: 10.1111/dom.14169.
    >> Share

  240. ADINOLFI LE, Petta S, Fracanzani AL, Nevola R, et al
    Reduced incidence of type 2 diabetes in patients with chronic hepatitis C virus infection cleared by direct-acting antivirals therapy. A prospective study.
    Diabetes Obes Metab. 2020 Aug 5. doi: 10.1111/dom.14168.
    >> Share

  241. VERMA S, McGuire DK, Bain SC, Bhatt DL, et al
    Effects of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across body mass index categories in type 2 diabetes: results of the LEADER and SUSTAIN 6 trials.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14160.
    >> Share

  242. WAN EYF, Yu EYT, Chen JY, Wong ICK, et al
    Associations between usual glycated haemoglobin A1c and Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus: A 10-year Diabetes cohort study.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14157.
    >> Share

  243. MIURA H, Sakaguchi K, Otowa-Suematsu N, Yamada T, et al
    Effects of Insulin Degludec and Insulin Glargine U300 on Glycemic Stability in Individuals with Type 1 Diabetes: a Multicenter, Randomized Controlled Crossover Study.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14161.
    >> Share

  244. MCEWAN P, Bennett H, Khunti K, Wilding J, et al
    Assessing the cost-effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14162.
    >> Share

  245. LI X, Zhu X, Liu J, Li Q, et al
    Pharmacokinetics, Pharmacodynamics, and Tolerability of Single- and Multiple-Doses of Janagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, in Chinese Subjects with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14156.
    >> Share

  246. WANNER C, Inzucchi SE, Zinman B, Koitka-Weber A, et al
    Consistent Effects of Empagliflozin on Cardiovascular and Kidney Outcomes Irrespective of Diabetic Kidney Disease Categories - Insights from the EMPA-REG OUTCOME trial.
    Diabetes Obes Metab. 2020 Aug 3. doi: 10.1111/dom.14158.
    >> Share

    July 2020
  247. MENEGHINI LF, Sullivan SD, Oster G, Busch R, et al
    A pragmatic randomized clinical trial of insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 6-month outcomes of ACHIEVE Control.
    Diabetes Obes Metab. 2020 Jul 30. doi: 10.1111/dom.14152.
    >> Share

  248. PRATLEY R, Dagogo-Jack S, Charbonnel B, Patel S, et al
    Efficacy and safety of ertugliflozin in older patients with type 2 diabetes mellitus: A pooled analysis of phase III studies.
    Diabetes Obes Metab. 2020 Jul 23. doi: 10.1111/dom.14150.
    >> Share

  249. HOME P, Blonde L, Kalra S, Ji L, et al
    Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared to premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesian network meta-analysis.
    Diabetes Obes Metab. 2020 Jul 22. doi: 10.1111/dom.14148.
    >> Share

  250. LEE DH, Chun EJ, Moon JH, Yun HM, et al
    Effect of cilostazol on carotid plaque volume measured by 3D ultrasound in patients with type 2 diabetes: FANCY study.
    Diabetes Obes Metab. 2020 Jul 22. doi: 10.1111/dom.14147.
    >> Share

  251. MATHIEU C, Dandona P, Birkenfeld AL, Krarup Hansen T, et al
    Benefit:Risk Profile of Dapagliflozin 5 mg in the DEPICT-1 and -2 Trials in Individuals with Type 1 Diabetes and BMI >/=27 kg/m(2).
    Diabetes Obes Metab. 2020 Jul 20. doi: 10.1111/dom.14144.
    >> Share

  252. MORIERI ML, Bonora BM, Longato E, Di Camilo B, et al
    Exposure to DPP-4 inhibitors and risk of pneumonia among people with type 2 diabetes. Retrospective cohort study and meta-analysis.
    Diabetes Obes Metab. 2020 Jul 20. doi: 10.1111/dom.14142.
    >> Share

  253. VERMA S, Bain SC, Honore JB, Mann JFE, et al
    Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials.
    Diabetes Obes Metab. 2020 Jul 9. doi: 10.1111/dom.14140.
    >> Share

  254. ZHOU X, Zhou Y, Li X, Xiao X, et al
    Safety concerns of SGLT-2 inhibitors in type 1 diabetes: a real-world study from the perspective of FAERS.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14138.
    >> Share

  255. VAS P, Hopkins D, Feher MD, Rubino F, et al
    Diabetes, Obesity and COVID-19: A Complex Interplay.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14134.
    >> Share

  256. HOME PD, Aroda VR, Blonde L, Guyot P, et al
    Efficacy and safety of iGlarLixi versus IDegLira in adults with type 2 diabetes inadequately controlled by glucagon-like peptide-1 receptor agonists (GLP-1RAs): a systematic literature review and indirect treatment comparison.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14136.
    >> Share

  257. NIELSEN R, Jorsal A, Tougaard RS, Rasmussen JJ, et al
    The impact of the Glucagon-Like Peptide-1 Receptor Agonist Liraglutide on Natriuretic Peptides in Heart Failure Patients with Reduced Ejection Fraction with and without Type 2 Diabetes.
    Diabetes Obes Metab. 2020 Jul 6. doi: 10.1111/dom.14135.
    >> Share

  258. AHERN AL, Griffin SJ, Wheeler GM, Sharp SJ, et al
    The effect of referral to an open-group behavioural weight management programme on the relative risk of normoglycaemia, non-diabetic hyperglycaemia and type 2 diabetes: secondary analysis of the WRAP trial.
    Diabetes Obes Metab. 2020 Jul 3. doi: 10.1111/dom.14123.
    >> Share

  259. RODBARD HW, Giaccari A, Lajara R, Stewart J, et al
    Sotagliflozin added to optimised insulin therapy leads to HbA1c reduction without weight gain in adults with type 1 diabetes: a pooled analysis of inTandem1 and inTandem2.
    Diabetes Obes Metab. 2020 Jul 3. doi: 10.1111/dom.14127.
    >> Share

    June 2020
  260. HEROLD KC, Reynolds J, Dziura J, Baidal D, et al
    Exenatide ER in patients with Type 1 diabetes with and without residual insulin production.
    Diabetes Obes Metab. 2020 Jun 23. doi: 10.1111/dom.14121.
    >> Share

  261. HAIDER KS, Haider A, Saad F, Doros G, et al
    Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.
    Diabetes Obes Metab. 2020 Jun 19. doi: 10.1111/dom.14122.
    >> Share

  262. JOHANSEN NJ, Dejgaard TF, Lund A, Schluntz C, et al
    Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
    Diabetes Obes Metab. 2020 Jun 16. doi: 10.1111/dom.14078.
    >> Share

  263. MENEGHINI L, Blonde L, Gill J, Dauchy A, et al
    Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naive adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomised, pragmatic real-life clinical trial.
    Diabetes Obes Metab. 2020 Jun 15. doi: 10.1111/dom.14116.
    >> Share

  264. BROWN RE, Bech PG, Aronson R
    Semaglutide Once Weekly in Persons with Type 2 Diabetes: Real-world Analysis of the Canadian LMC Diabetes Registry (SPARE Study).
    Diabetes Obes Metab. 2020 Jun 15. doi: 10.1111/dom.14117.
    >> Share

  265. DANNE T, Matsuhisa M, Sussebach C, Goyeau H, et al
    Lower Risk for Severe Hypoglycaemia with Insulin Glargine 300 U/mL vs Glargine 100 U/mL in Participants with Type 1 Diabetes: a Meta-Analysis of 6-Month Phase 3 Clinical Trials.
    Diabetes Obes Metab. 2020 Jun 9. doi: 10.1111/dom.14109.
    >> Share

  266. WU J, Zhang J, Sun X, Wang L, et al
    Influence of diabetes mellitus on the severity and fatality of SARS-CoV-2 infection.
    Diabetes Obes Metab. 2020 Jun 4. doi: 10.1111/dom.14105.
    >> Share

  267. SVANE MS, Johannesen HH, Martinussen C, Bojsen-Moller KN, et al
    No effects of a six-week intervention with glucagon-like peptide-1 receptor analogue on pancreatic volume and edema in obese men without diabetes.
    Diabetes Obes Metab. 2020 Jun 4. doi: 10.1111/dom.14106.
    >> Share

  268. LADWA M, Bello O, Hakim O, Shojaee-Moradie F, et al
    Insulin clearance as the major player in the hyperinsulinaemia of black African men without diabetes.
    Diabetes Obes Metab. 2020 Jun 2. doi: 10.1111/dom.14101.
    >> Share

  269. KLAFF L, Cao D, Dellva MA, Tobian J, et al
    Ultra Rapid Lispro Improves Postprandial Glucose Control Compared With Lispro in Patients With Type 1 Diabetes: Results from the 26-Week PRONTO-T1D Study.
    Diabetes Obes Metab. 2020 Jun 2. doi: 10.1111/dom.14100.
    >> Share

  270. KRAAIJENHOF J, Muskiet MHA, Tonneijck L, Ouwens DM, et al
    Effects of DPP-4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8-week randomized controlled double-blind trial.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14107.
    >> Share

  271. MANTSIOU C, Karagiannis T, Kakotrichi P, Malandris K, et al
    Glucagon-like peptide 1 receptor agonists and sodium glucose co-transporter 2 inhibitors as combination therapy for type 2 diabetes. A systematic review and meta-analysis.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14108.
    >> Share

  272. COOMANS DE BRACHENE A, Castela A, Op de Beeck A, Mirmira RG, et al
    Pre-clinical evaluation of TYK2 inhibitors for human beta cell protection in type 1 diabetes.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14104.
    >> Share

  273. OHKUMA T, Peters SAE, Jun M, Harrap S, et al
    Sex-specific associations between cardiovascular risk factors and myocardial infarction in patients with type 2 diabetes: the ADVANCE-ON study.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14103.
    >> Share

  274. CONSOLI A, Czupryniak L, Duarte R, Jermendy G, et al
    Positioning sulfonylureas in a modern treatment algorithm for patients with type 2 diabetes: expert opinion from a European Consensus Panel.
    Diabetes Obes Metab. 2020 Jun 1. doi: 10.1111/dom.14102.
    >> Share

    May 2020
  275. LI H, Tian S, Chen T, Cui Z, et al
    Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19.
    Diabetes Obes Metab. 2020 May 29. doi: 10.1111/dom.14099.
    >> Share

  276. FADINI GP, Morieri ML, Longato E, Bonora BM, et al
    Exposure to DPP-4 inhibitors and COVID-19 among people with type 2 diabetes. A case-control study.
    Diabetes Obes Metab. 2020 May 28. doi: 10.1111/dom.14097.
    >> Share

  277. WAN EYF, Yu EYT, Chin WY, Barrett JK, et al
    Greater variability in lipid measurements associated with cardiovascular disease and mortality: 10-year diabetes cohort study.
    Diabetes Obes Metab. 2020 May 26. doi: 10.1111/dom.14093.
    >> Share

  278. WANG W, Zhang L, Pei X, Pan Q, et al
    Evaluation of the safety of SGLT-2 inhibitors for treating patients with type 1 diabetes.
    Diabetes Obes Metab. 2020 May 21. doi: 10.1111/dom.14092.
    >> Share

  279. KANETO H, Koshida R, Baxter M
    Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.
    Diabetes Obes Metab. 2020 May 20. doi: 10.1111/dom.14095.
    >> Share

  280. GHANIM H, Batra M, Green K, Abuaysheh S, et al
    Liraglutide Treatment in Overweight and Obese Patients with Type 1 Diabetes: A 26 weeks Randomized Controlled Trial.
    Diabetes Obes Metab. 2020 May 19. doi: 10.1111/dom.14090.
    >> Share

  281. BORNER T, Shaulson ED, Tinsley IC, Stein LM, et al
    A second generation GLP-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models.
    Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14089.
    >> Share

  282. ZHANG Y, Li H, Zhang J, Cao Y, et al
    The Clinical Characteristics and Outcomes of Diabetes Mellitus and Secondary Hyperglycaemia Patients with Coronavirus Disease 2019: a Single-center, Retrospective, Observational Study in Wuhan.
    Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14086.
    >> Share

  283. KIM SG, Kim KJ, Yoon KH, Chun SW, et al
    Efficacy and safety of lobeglitazone versus sitagliptin as an add-on to metformin in type 2 diabetes with metabolic syndrome over 24 weeks.
    Diabetes Obes Metab. 2020 May 14. doi: 10.1111/dom.14085.
    >> Share

  284. PRATTICHIZZO F, Giuliani A, Sabbatinelli J, Matacchione G, et al
    Prevalence of residual inflammatory risk and associated clinical variables in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2020 May 11. doi: 10.1111/dom.14081.
    >> Share

  285. MOSER O, Dietrich M, McCarthy O, Bracken RM, et al
    Bolus insulin dose depends on previous-day race intensity during 5 days of professional road-cycle racing in athletes with type 1 diabetes - a prospective observational study.
    Diabetes Obes Metab. 2020 May 8. doi: 10.1111/dom.14083.
    >> Share

  286. RAJPAL A, Ismail-Beigi F
    Intermittent Fasting and "Metabolic Switch": Effects on Metabolic Syndrome, Pre-diabetes and Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2020 May 6. doi: 10.1111/dom.14080.
    >> Share

  287. LIU J, Li L, Li S, Wang Y, et al
    SGLT2 inhibitors and risk of diabetic ketoacidosis in patients with type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2020 May 4. doi: 10.1111/dom.14075.
    >> Share

  288. ZHOU C, Liu M, Zhang Z, Zhang Y, et al
    Positive association of serum uric acid with new-onset diabetes in hypertensive Chinese females found in a retrospective analysis of the China Stroke Primary Prevention Trial (CSPPT).
    Diabetes Obes Metab. 2020 May 3. doi: 10.1111/dom.14072.
    >> Share

  289. BIRKELAND KI, Bodegard J, Eriksson JW, Norhammar A, et al
    Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study.
    Diabetes Obes Metab. 2020 May 3. doi: 10.1111/dom.14074.
    >> Share

  290. MOREA N, Retnakaran R, Vidal J, Aroda VR, et al
    iGlarLixi effectively reduces residual hyperglycemia in patients with type 2 diabetes on basal insulin: a post hoc analysis from the LixiLan-L study.
    Diabetes Obes Metab. 2020 May 3. doi: 10.1111/dom.14077.
    >> Share

    April 2020
  291. PERSSON S, Johansen P, Andersson E, Lindgren P, et al
    Days absent from work due to complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden.
    Diabetes Obes Metab. 2020 Apr 24. doi: 10.1111/dom.14070.
    >> Share

  292. SHAH VN, Grimsmann JM, Foster N, Dost A, et al
    Undertreatment of Cardiovascular Risk factors in the Type 1 Diabetes Exchange Clinic Network (USA) and the Prospective Diabetes Follow-up (Germany/Austria) Registries.
    Diabetes Obes Metab. 2020 Apr 24. doi: 10.1111/dom.14069.
    >> Share

  293. VAN DER AART-VAN DER BEEK AB, van Raalte DH, Guja C, Hoogenberg K, et al
    Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: pooled analysis of randomized active controlled clinical trials.
    Diabetes Obes Metab. 2020 Apr 23. doi: 10.1111/dom.14067.
    >> Share

  294. DEL PRATO S, Frias JP, Blonde L, Aroda VR, et al
    Impact of disease duration and beta-cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on GLP-1 receptor agonist therapy: Exploratory analyses from the LixiLan-G trial.
    Diabetes Obes Metab. 2020 Apr 23. doi: 10.1111/dom.14068.
    >> Share

  295. KIM G, Lim S, Kwon HS, Park IB, et al
    Efficacy and safety of evogliptin treatment in patients with type 2 diabetes: A multicenter, active-controlled, randomized, double-blind study with open-label extension (EVERGREEN study).
    Diabetes Obes Metab. 2020 Apr 21. doi: 10.1111/dom.14061.
    >> Share

  296. BOLLI GB, Landgraf W, Bosnyak Z, Melas-Melt L, et al
    Hypoglycaemia risk with insulin glargine 300 U/mL compared with glargine 100 U/mL across different baseline fasting C-peptide levels in insulin-naive people with type 2 diabetes: a post hoc analysis of the EDITION 3 trial.
    Diabetes Obes Metab. 2020 Apr 21. doi: 10.1111/dom.14065.
    >> Share

  297. KAHKOSKA AR, Geybels MS, Klein KR, Kreiner FF, et al
    Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN-6 cardiovascular outcomes trials.
    Diabetes Obes Metab. 2020 Apr 20. doi: 10.1111/dom.14063.
    >> Share

  298. KITAZAWA T, Seino H, Ohashi H, Inazawa T, et al
    Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus DPP-4 inhibitor in Japanese type 2 diabetes patients: a randomized, 24-week, open label, controlled trial (STOP-OB).
    Diabetes Obes Metab. 2020 Apr 20. doi: 10.1111/dom.14059.
    >> Share

  299. MATHIEU C, Rudofsky G, Phillip M, Araki E, et al
    Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trial.
    Diabetes Obes Metab. 2020 Apr 20. doi: 10.1111/dom.14060.
    >> Share

  300. TERAUCHI Y, Nakama T, Spranger R, Amano A, et al
    Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: T
    Diabetes Obes Metab. 2020 Apr 14. doi: 10.1111/dom.14036.
    >> Share

  301. GIORGINO F, Vora J, Fenici P, Solini A, et al
    Cardiovascular protection with SGLT2 inhibitors in type 2 diabetes mellitus: does it apply to all patients?
    Diabetes Obes Metab. 2020 Apr 14. doi: 10.1111/dom.14055.
    >> Share

  302. ZHANG XM, Ma Y, Chen H, Lou Y, et al
    A pragmatic study of mid-mixture insulin and basal insulin treatment in patients with type 2 diabetes uncontrolled with oral antihyperglycemic medications: A lesson from real-world experience.
    Diabetes Obes Metab. 2020 Apr 8. doi: 10.1111/dom.14052.
    >> Share

  303. THETHI TK, Pratley R, Meier JJ
    Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: The PIONEER programme.
    Diabetes Obes Metab. 2020 Apr 8. doi: 10.1111/dom.14054.
    >> Share

  304. RUNESSON B, Xu Y, Qureshi AR, Lindholm B, et al
    Association between reduced kidney function and incident hypoglycemia in people with diabetes; the Stockholm CREAtinine Measurements (SCREAM) project.
    Diabetes Obes Metab. 2020 Apr 6. doi: 10.1111/dom.14051.
    >> Share

  305. HELLER S, Lingvay I, Marso SP, Philis-Tsimikas A, et al
    Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE.
    Diabetes Obes Metab. 2020 Apr 6. doi: 10.1111/dom.14049.
    >> Share

  306. DUBE MC, D'Amours M, Weisnagel SJ
    Effect of liraglutide on food consumption, appetite sensations and eating behaviours in overweight subjects with type 1 diabetes.
    Diabetes Obes Metab. 2020 Apr 6. doi: 10.1111/dom.14050.
    >> Share

  307. BUTLER J, Januzzi JL, Rosenstock J
    Management of heart failure and type 2 diabetes mellitus: Maximizing complementary drug therapy.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14042.
    >> Share

  308. CRESCI B, Cosentino C, Monami M, Mannucci E, et al
    Metabolic Surgery for the Treatment of Type 2 Diabetes: A Network Metanalysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14045.
    >> Share

  309. HALUZIK M, Cheng A, Muller-Wieland D, Westerbacka J, et al
    Differential glycaemic control with basal insulin glargine 300 U/mL versus degludec 100 U/mL according to kidney function in type 2 diabetes - a subanalysis from the BRIGHT trial.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14043.
    >> Share

  310. CAO JY, Waldman B, O'Connell R, Sullivan, et al
    Uric Acid Predicts Long-Term Cardiovascular Risk in Type 2 Diabetes but Does Not Mediate the Benefits of Fenofibrate: the FIELD Study.
    Diabetes Obes Metab. 2020 Apr 3. doi: 10.1111/dom.14046.
    >> Share

  311. CAHN A, Raz I, Bonaca M, Mosenzon O, et al
    Safety of dapagliflozin in a broad population of patients with type 2 diabetes - analyses from the DECLARE - TIMI 58 study.
    Diabetes Obes Metab. 2020 Apr 2. doi: 10.1111/dom.14041.
    >> Share

  312. SAEED MI, Eklof J, Achir I, Sivapalan P, et al
    Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease.
    Diabetes Obes Metab. 2020 Apr 1. doi: 10.1111/dom.14040.
    >> Share

  313. SELBY NM, Taal MW
    An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines.
    Diabetes Obes Metab. 2020;22 Suppl 1:3-15.
    >> Share

  314. STEPHENS JW, Brown KE, Min T
    Chronic kidney disease in type 2 diabetes: Implications for managing glycaemic control, cardiovascular and renal risk.
    Diabetes Obes Metab. 2020;22 Suppl 1:32-45.
    >> Share

  315. BARRERA-CHIMAL J, Jaisser F
    Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
    Diabetes Obes Metab. 2020;22 Suppl 1:16-31.
    >> Share

  316. AL DHAYBI O, Bakris GL
    Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
    Diabetes Obes Metab. 2020;22 Suppl 1:69-76.
    >> Share

  317. SEEGER JD, Nunes A, Loughlin AM
    Using RWE research to extend clinical trials in diabetes: An example with implications for the future.
    Diabetes Obes Metab. 2020;22 Suppl 3:35-44.
    >> Share

  318. ZACCARDI F, Davies MJ, Khunti K
    The present and future scope of real-world evidence research in diabetes: What questions can and cannot be answered and what might be possible in the future?
    Diabetes Obes Metab. 2020;22 Suppl 3:21-34.
    >> Share

  319. PATORNO E, Schneeweiss S, Wang SV
    Transparency in real-world evidence (RWE) studies to build confidence for decision-making: Reporting RWE research in diabetes.
    Diabetes Obes Metab. 2020;22 Suppl 3:45-59.
    >> Share

  320. MARRE M
    Importance of intensive blood pressure control in type 2 diabetes: Mechanisms, treatments and current guidelines.
    Diabetes Obes Metab. 2020;22 Suppl 2:33-42.
    >> Share

    March 2020
  321. JODAR E, Michelsen M, Polonsky WH, Rea R, et al
    Semaglutide improves health-related quality of life vs placebo when added to standard of care in patients with type 2 diabetes at high cardiovascular risk (SUSTAIN 6).
    Diabetes Obes Metab. 2020 Mar 30. doi: 10.1111/dom.14039.
    >> Share

  322. VERMA S, Sharma A, Zinman B, Ofstad AP, et al
    Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial.
    Diabetes Obes Metab. 2020 Mar 29. doi: 10.1111/dom.14015.
    >> Share

  323. WAN EYF, Yu EYT, Chin WY, Yan FT, et al
    Age-specific Associations of HbA1c Variability with Cardiovascular Disease and Mortality in Type 2 Diabetes Mellitus Patients: A 10-year cohort study.
    Diabetes Obes Metab. 2020 Mar 20. doi: 10.1111/dom.14034.
    >> Share

  324. YOON KH, Kang J, Kwon SC, Trautmann ME, et al
    Pharmacokinetic and dose-finding studies of efpeglenatide in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Mar 16. doi: 10.1111/dom.14032.
    >> Share

  325. DICEMBRINI I, Pala L, Caliri M, Minardi S, et al
    combined continuous glucose monitoring and subcutaneous insulin infusion versus self-monitoring of blood glucose with optimized multiple injections in type 1 diabetes: A randomized cross-over trial.
    Diabetes Obes Metab. 2020 Mar 12. doi: 10.1111/dom.14028.
    >> Share

  326. DE BOER SA, Reijrink M, Abdulahad WH, Hoekstra ES, et al
    Angiogenic T cells are decreased in people with type 2 diabetes mellitus and recruited by the dipeptidyl peptidase-4 inhibitor Linagliptin. A subanalysis from a randomized, placebo controlled trial (RELEASE study).
    Diabetes Obes Metab. 2020 Mar 12. doi: 10.1111/dom.14024.
    >> Share

  327. COUSSA A, Bassil M, Gougeon R, Marliss EB, et al
    Glucose and protein metabolic responses to an energy- but not protein- restricted diet in type 2 Diabetes.
    Diabetes Obes Metab. 2020 Mar 12. doi: 10.1111/dom.14026.
    >> Share

  328. BUZZETTI R, Zampetti S, Pozzilli P
    The Impact Of Obesity On The Increasing Incidence Of Type 1 Diabetes.
    Diabetes Obes Metab. 2020 Mar 10. doi: 10.1111/dom.14022.
    >> Share

  329. WEBB DR, Htike ZZ, Swarbrick DJ, Brady EM, et al
    A randomised, open label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes.
    Diabetes Obes Metab. 2020 Mar 10. doi: 10.1111/dom.14023.
    >> Share

  330. DEL PRATO S, Kang J, Trautmann ME, Stewart J, et al
    Efficacy and safety of once-monthly efpeglenatide in patients with type 2 diabetes: Results of a phase 2 placebo-controlled, 16-week randomized dose-finding study.
    Diabetes Obes Metab. 2020 Mar 3. doi: 10.1111/dom.14020.
    >> Share

  331. MATSUHISA M, Takita Y, Nasu R, Nagai Y, et al
    Nasal Glucagon as a Viable Alternative to Treat Insulin-induced Hypoglycemia in Japanese Patients with Type 1 and Type 2 Diabetes: A Phase 3 Randomized Crossover Study.
    Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14019.
    >> Share

  332. MULDER S, Hammarstedt A, Nagaraj SB, Nair V, et al
    A metabolomics based molecular pathway analysis for how the SGLT2-inhibitor dapagliflozin may slow kidney function decline in patients with diabetes.
    Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14018.
    >> Share

  333. DAVIDSON MB
    Second Generation Basal Insulins to Initiate Insulin Therapy in Type 2 Diabetes: Need for Clinical Evidence Before Incurring Increased Costs.
    Diabetes Obes Metab. 2020 Mar 1. doi: 10.1111/dom.14016.
    >> Share

    February 2020
  334. SINCLAIR AJ, Heller SR, Pratley RE, Duan R, et al
    Evaluating glucose-lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial.
    Diabetes Obes Metab. 2020 Feb 26. doi: 10.1111/dom.14013.
    >> Share

  335. DERUAZ-LUYET A, Raabe C, Garry EM, Brodovicz KG, et al
    Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States between 2010 and 2014.
    Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14012.
    >> Share

  336. BAJAJ HS, Raz I, Mosenzon O, Murphy SA, et al
    Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: analyses from the DECLARE-TIMI 58 trial.
    Diabetes Obes Metab. 2020 Feb 23. doi: 10.1111/dom.14011.
    >> Share

  337. WENTWORTH JM, Colman PG
    The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: a randomized placebo-controlled trial.
    Diabetes Obes Metab. 2020 Feb 19. doi: 10.1111/dom.14009.
    >> Share

  338. CURTIN F, Champion B, Davoren P, Duke S, et al
    A Safety and Pharmacodynamics Study of Temelimab, an anti-HERV-W-Env Monoclonal Antibody, in Type 1 Diabetes Patients.
    Diabetes Obes Metab. 2020 Feb 19. doi: 10.1111/dom.14010.
    >> Share

  339. KANETO H, Takami A, Spranger R, Amano A, et al
    Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-L Randomized Clinical Tria
    Diabetes Obes Metab. 2020 Feb 19. doi: 10.1111/dom.14005.
    >> Share

  340. JOHANSSON L, Hockings PD, Johnsson E, Dronamraju N, et al
    Dapagliflozin plus saxagliptin add-on to metformin reduces liver fat and adipose tissue volume in patients with type 2 diabetes.
    Diabetes Obes Metab. 2020 Feb 18. doi: 10.1111/dom.14004.
    >> Share

  341. FRIAS JP, Gonzalez-Galvez G, Johnsson E, Maaske J, et al
    Efficacy and safety of dual add-on therapy with dapagliflozin plus saxagliptin versus glimepiride in patients with poorly controlled type 2 diabetes on a stable dose of metformin: Results from a 52-week, randomized, active-controlled trial.
    Diabetes Obes Metab. 2020 Feb 12. doi: 10.1111/dom.13997.
    >> Share

  342. MUNCH M, Meyer L, Hannedouche T, Kunz K, et al
    Effect of Adding Vildagliptin to Insulin in Hemodialyzed Patients with Type 2 Diabetes: A Randomized Multicentric Prospective Study-The VILDDIAL Study.
    Diabetes Obes Metab. 2020 Feb 11. doi: 10.1111/dom.13988.
    >> Share

  343. IRACE C, Cutruzzola A, Nuzzi A, Assaloni R, et al
    Clinical Use of a 180-Day Implantable Glucose Sensor Improves Glycated Hemoglobin and Time in Range in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13993.
    >> Share

  344. BENNETT H, Tank A, Evans M, Bergenheim K, et al
    Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of Type 1 Diabetes Mellitus in the UK.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13992.
    >> Share

  345. COOPER ME, Rosenstock J, Kadowaki T, Seino Y, et al
    Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA(R) trial.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13995.
    >> Share

  346. SCHERNTHANER G, Groop PH, Kalra PA, Ronco C, et al
    SGLT-2 Inhibitor Renal Outcome Modification in Type-2 Diabetes: Evidence from Studies in Patients with High or Low Renal Risk.
    Diabetes Obes Metab. 2020 Feb 9. doi: 10.1111/dom.13994.
    >> Share

  347. VERMA S, Ji Q, Bhatt DL, Mazer CD, et al
    The Association Between Uric Acid Levels and Cardio-renal Outcomes and Death in Patients with Type 2 Diabetes: A Subanalysis of EMPA-REG OUTCOME.
    Diabetes Obes Metab. 2020 Feb 6. doi: 10.1111/dom.13991.
    >> Share

  348. BOUTER KEC, van Bommel EJM, Jansen H, van Harskamp D, et al
    The effect of dapagliflozin on apolipoprotein B and glucose fluxes in patients with type 2 diabetes and well controlled plasma LDL cholesterol.
    Diabetes Obes Metab. 2020 Feb 5. doi: 10.1111/dom.13990.
    >> Share

  349. KATSIKI N, Ofori-Asenso R, Ferrannini E, Mazidi M, et al
    Fixed-dose combination of empagliflozin and linagliptin for the treatment of patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2020 Feb 5. doi: 10.1111/dom.13989.
    >> Share

  350. TUTTLE KR, McGill JB
    Evidence-based treatment of hyperglycemia with incretin therapies in patients with type 2 diabetes mellitus and advanced chronic kidney disease.
    Diabetes Obes Metab. 2020 Feb 3. doi: 10.1111/dom.13986.
    >> Share

  351. PETRIE JR, Rossing PR, Campbell IW
    Metformin and cardiorenal outcomes in diabetes: a reappraisal.
    Diabetes Obes Metab. 2020 Feb 3. doi: 10.1111/dom.13984.
    >> Share

  352. SILVERII GA, Dicembrini I, Monami M, Mannucci E, et al
    Fournier's gangrene and sodium-glucose co-transporter-2 inhibitors: A meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2020;22:272-275.
    >> Share

  353. SATO Y, Nunoi K, Kaku K, Yoshida A, et al
    Basal insulin secretion capacity predicts the initial response and maximum levels of beta-hydroxybutyrate during therapy with the sodium-glucose co-transporter-2 inhibitor tofogliflozin, in relation to weight loss.
    Diabetes Obes Metab. 2020;22:222-230.
    >> Share

  354. JUNG HH, Lee S
    Optimal fasting glucose levels with regard to cardiovascular and mortality outcomes in people treated with or without antidiabetic medication.
    Diabetes Obes Metab. 2020;22:243-253.
    >> Share

  355. MANNUCCI E, Dicembrini I, Nreu B, Monami M, et al
    Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Diabetes Obes Metab. 2020;22:203-211.
    >> Share

  356. BANG C, Mortensen MB, Lauridsen KG, Bruun JM, et al
    Trends in antidiabetic drug utilization and expenditure in Denmark: A 22-year nationwide study.
    Diabetes Obes Metab. 2020;22:167-172.
    >> Share

    January 2020
  357. VILSBOLL T, Ekholm E, Johnsson E, Garcia-Sanchez R, et al
    Efficacy and safety of dapagliflozin plus saxagliptin versus insulin glargine over 52 weeks as add-on to metformin with or without sulfonylurea in patients with type 2 diabetes: A randomized, parallel-design, open-label, phase 3 trial.
    Diabetes Obes Metab. 2020 Jan 31. doi: 10.1111/dom.13981.
    >> Share

  358. ISMAIL HM, Becker DJ, Libman I, Herold KC, et al
    Early and Late C-peptide Responses during Oral Glucose Tolerance Testing are Oppositely Predictive of Type 1 Diabetes in Autoantibody Positive Individuals.
    Diabetes Obes Metab. 2020 Jan 31. doi: 10.1111/dom.13982.
    >> Share

  359. NEUMAN V, Pruhova S, Kulich M, Kolouskova S, et al
    Gluten-free diet in children with recent-onset type 1 diabetes: a 12-month intervention trial.
    Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13974.
    >> Share

  360. BLONDE L, Belousova L, Fainberg U, Garcia-Hernandez PA, et al
    Liraglutide as add-on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13978.
    >> Share

  361. FRIAS JP, Nauck MA, Van J, Benson C, et al
    Efficacy and Tolerability of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist in Patients with Type 2 Diabetes: A 12-Week, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate Different Dose-Escalation Regimens.
    Diabetes Obes Metab. 2020 Jan 27. doi: 10.1111/dom.13979.
    >> Share

  362. GORDON J, Beresford-Hulme L, Bennett H, Tank A, et al
    The relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: observations from the DEPICT clinical trial programme.
    Diabetes Obes Metab. 2020 Jan 22. doi: 10.1111/dom.13972.
    >> Share

  363. JI L, Wan H, Wen B, Wang X, et al
    Higher versus standard starting dose of insulin glargine 100 U/mL in overweight or obese Chinese patients with type 2 diabetes: results of a multicentre, open-label, randomised controlled trial (BEYOND VII).
    Diabetes Obes Metab. 2020 Jan 15. doi: 10.1111/dom.13967.
    >> Share

  364. LING S, Sun P, Zaccardi F, Khosla S, et al
    Durability of glycaemic control in patients with type 2 diabetes after metformin failure: prognostic model derivation and validation using the DISCOVER study.
    Diabetes Obes Metab. 2020 Jan 15. doi: 10.1111/dom.13966.
    >> Share

  365. SCIANNAMEO V, Berchialla P, Orsi E, Lamacchia O, et al
    Enrolment criteria for diabetes cardiovascular outcome trials do not inform on generalizability to clinical practice. The case of GLP-1 receptor agonists.
    Diabetes Obes Metab. 2020 Jan 14. doi: 10.1111/dom.13962.
    >> Share

  366. SINGH P, Taufeeq M, Pesavento TE, Washburn K, et al
    Comparison of two glucagon-like-peptide-1 analogs (GLP -1) dulaglutide vs liraglutide for the management of diabetes in solid organ transplant (SOT): a retrospective study.
    Diabetes Obes Metab. 2020 Jan 13. doi: 10.1111/dom.13964.
    >> Share

  367. FRALICK M, MacFadden DR
    A hypothesis for why SGLT2 inhibitors have been found to cause genital infection, but not urinary tract infection.
    Diabetes Obes Metab. 2020 Jan 13. doi: 10.1111/dom.13959.
    >> Share

  368. PACKER M
    Interplay of AMPK/SIRT1 Activation and Sodium Influx Inhibition Mediates the Renal Benefits of SGLT2 Inhibitors in Type 2 Diabetes: a Novel Conceptual Framework.
    Diabetes Obes Metab. 2020 Jan 9. doi: 10.1111/dom.13961.
    >> Share

  369. BURGGRAAF B, Pouw N, Fernandez Arroyo S, van Vark-van der Zee Lc LC, et al
    A Placebo-controlled Proof-of-Concept Study of Alirocumab on Postprandial Lipids and Vascular Elasticity in Insulin-treated patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2020 Jan 7. doi: 10.1111/dom.13960.
    >> Share

  370. KONG APS, Lew T, Lau ESH, Lim LL, et al
    Real-world data reveal unmet clinical needs in insulin treatment in Asians with type 2 diabetes - the Joint Asia Diabetes Evaluation (JADE) Register.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13950.
    >> Share

  371. SESTI G, Bardtrum L, Dagdelen S, Halladin N, et al
    A greater proportion of participants with type 2 diabetes achieve treatment targets with IDegLira (insulin degludec/liraglutide) versus insulin glargine U100 at 26 weeks: DUAL VIII a randomized trial designed to resemble clinical practice.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13957.
    >> Share

  372. DAWWAS GK, Leonard CE, Garg M, Vouri SM, et al
    12-Year Trends in Pharmacologic Treatment of Type 2 Diabetes among Patients with Heart Failure in the United States.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13949.
    >> Share

  373. TSENG JY, Chen HH, Huang KC, Hsu SP, et al
    Effect of mean HbA1c on the association of HbA1c variability and all-cause mortality in patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13951.
    >> Share

  374. PHILIS-TSIMIKAS A, Lane W, Pedersen-Bjergaard U, Wysham C, et al
    The relationship between HbA1c and hypoglycaemia in patients with diabetes treated with insulin degludec versus insulin glargine 100 units/mL.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13954.
    >> Share

  375. HUSAIN M, Bain SC, Jeppesen OK, Lingvay I, et al
    Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13955.
    >> Share

  376. BAASCH-SKYTTE T, Lemgart CT, Oehlenschlager MH, Petersen PE, et al
    Efficacy of 10-20-30 training versus moderate-intensity continuous training on HbA1c , body composition and maximum oxygen uptake in male patients with type 2 diabetes: A randomized controlled trial.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13953.
    >> Share

  377. PFOHL M, Jornayvaz FR, Fritsche A, Pscherer S, et al
    Effectiveness and Safety of Insulin Glargine 300 U/mL in Insulin-Naive Patients with Type 2 Diabetes after Failure of Oral Therapy in a Real World Setting.
    Diabetes Obes Metab. 2020 Jan 5. doi: 10.1111/dom.13952.
    >> Share

  378. IDRIS I
    News and Views January 2020: Highlights from the European Association of the Study of Diabetes (EASD) Scientific Meeting 2019.
    Diabetes Obes Metab. 2020;22:135-137.
    >> Share

    December 2019
  379. GRUNBERGER G, Bhargava A, Ly T, Zisser H, et al
    Human Regular U-500 Insulin via Continuous Subcutaneous Insulin Infusion vs. Multiple Daily Injections in Adults with Type 2 Diabetes: the VIVID Study.
    Diabetes Obes Metab. 2019 Dec 22. doi: 10.1111/dom.13947.
    >> Share

  380. KHUNTI K, Giorgino F, Berard L, Mauricio D, et al
    The importance of the initial period of basal insulin titration in people with diabetes.
    Diabetes Obes Metab. 2019 Dec 22. doi: 10.1111/dom.13946.
    >> Share

  381. PERKINS BA, Soleymanlou N, Rosenstock J, Skyler JS, et al
    Low-Dose Empagliflozin as Adjunct-to-Insulin Therapy in Type 1 Diabetes: A Valid Modeling and Simulation Analysis to Confirm Efficacy.
    Diabetes Obes Metab. 2019 Dec 19. doi: 10.1111/dom.13945.
    >> Share

  382. THIEU VT, Mitchell BD, Varnado OJ, Frier BM, et al
    Treatment and prevention of severe hypoglycaemia in people with diabetes: current and new formulations of glucagon.
    Diabetes Obes Metab. 2019 Dec 9. doi: 10.1111/dom.13941.
    >> Share

  383. VISENTIN R, Schiavon M, Gobel B, Riz M, et al
    Dual GLP-1R/GCGR Agonist SAR425899 Improves Beta-cell Function in Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Dec 5. doi: 10.1111/dom.13939.
    >> Share

  384. DANIELE G, Tura A, Dardano A, Bertolotto A, et al
    Effects of Treatment With Metformin and/or Sitagliptin on Beta-cell Function and Insulin Resistance in Prediabetic Women With Previous Gestational Diabetes.
    Diabetes Obes Metab. 2019 Dec 4. doi: 10.1111/dom.13940.
    >> Share

  385. JI L, Kang ES, Dong X, Li L, et al
    Efficacy and Safety of Insulin Glargine 300 U/mL versus Insulin Glargine 100 U/mL in Asia Pacific Insulin-Naive People with Type 2 Diabetes: The EDITION AP Randomised Controlled Trial.
    Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13936.
    >> Share

  386. LIU J, Patel S, Cater NB, Wu L, et al
    Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13931.
    >> Share

  387. MEIER JJ, Menge BA, Schenker N, Erdmann S, et al
    Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal-related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Dec 3. doi: 10.1111/dom.13935.
    >> Share

  388. ALSALIM W, Goransson O, Tura A, Pacini G, et al
    Persistent whole day meal effects of three dipeptidyl peptidase-4 inhibitors on glycemia and hormonal responses in metformin-treated type 2 diabetes.
    Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13934.
    >> Share

  389. AKTURK HK, Giordano D, Champakanath A, Brackett S, et al
    Long-term Real-life Glycemic Outcomes with Hybrid Closed-Loop System when Compared with Sensor-Augmented Pump Therapy in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13933.
    >> Share

  390. PETTUS JH, Zhou FL, Shepherd L, Mercaldi K, et al
    Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: a real-world study of more than 30 000 patients in a United States electronic health record database.
    Diabetes Obes Metab. 2019 Dec 2. doi: 10.1111/dom.13937.
    >> Share

    November 2019
  391. HALVORSEN YD, Walford G, Thurber T, Russell H, et al
    A Twelve-Week, Randomized, Double-Blind, Placebo-Controlled, Four-Arm Dose-Finding Phase 2 Study Evaluating Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Nov 20. doi: 10.1111/dom.13928.
    >> Share

  392. ARAKI E, Watada H, Uchigata Y, Tomonaga O, et al
    Efficacy and safety of dapagliflozin in Japanese patients with inadequately controlled type 1 diabetes (DEPICT-5): 52-week results from a randomized, open-label, phase III clinical trial.
    Diabetes Obes Metab. 2019 Nov 19. doi: 10.1111/dom.13922.
    >> Share

  393. SCHOLTES RA, van Raalte DH, Correa-Rotter R, Toto RD, et al
    The effects of dapagliflozin on cardio-renal risk factors in patients with type 2 diabetes with or without renin-angiotensin inhibitor treatment: a post hoc analysis.
    Diabetes Obes Metab. 2019 Nov 19. doi: 10.1111/dom.13923.
    >> Share

  394. KNUDSEN ST, Cooper ME
    Renal Protection: What Have We Learnt From ADVANCE About Kidney Disease in Type 2 Diabetes?
    Diabetes Obes Metab. 2019 Nov 14. doi: 10.1111/dom.13917.
    >> Share

  395. HEISE T, Donnelly C, Barve A, Aubonnet P, et al
    Pharmacokinetic and Pharmacodynamic Bioequivalence of Proposed Biosimilar MYL-1501D With US and EU Insulin Glargine Formulations in Patients With Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2019 Nov 13. doi: 10.1111/dom.13919.
    >> Share

  396. VIANNA AGD, Lacerda CS, Pechmann LM, Polesel MG, et al
    Improved Glycemic Variability and Time in Range with Dapagliflozin versus Gliclazide Modified Release among Adults with Type 2 Diabetes Evaluated by Continuous Glucose Monitoring: A 12-week Randomized Controlled Trial.
    Diabetes Obes Metab. 2019 Nov 10. doi: 10.1111/dom.13913.
    >> Share

  397. DUFFUS SH, Al Ta'ani Z, Slaughter JC, Niswender KD, et al
    Increased Proportion of Time in Hybrid Closed-Loop "Auto Mode" is Associated with Improved Glycemic Control for Adolescent and Young Adult Type 1 Diabetes Patients Using the MiniMed 670G Insulin Pump.
    Diabetes Obes Metab. 2019 Nov 10. doi: 10.1111/dom.13912.
    >> Share

  398. MORRIS E, Aveyard P, Dyson P, Noreik M, et al
    A food-based low-energy, low-carbohydrate diet for people with type 2 diabetes in primary care: a randomised controlled feasibility trial.
    Diabetes Obes Metab. 2019 Nov 10. doi: 10.1111/dom.13915.
    >> Share

  399. DEJGAARD TF, Schmidt S, Frandsen CS, Vistisen D, et al
    Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial - a randomized, double-blinded, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13911.
    >> Share

  400. XIE C, Wang X, Jones KL, Horowitz M, et al
    Role of endogenous glucagon-like peptide-1 enhanced by vildagliptin in the glycaemic and energy expenditure responses to intraduodenal fat infusion in type 2 diabetes.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13906.
    >> Share

  401. SONE H, Kaneko T, Shiki K, Tachibana Y, et al
    Efficacy and safety of empagliflozin as add-on to insulin in Japanese patients with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13909.
    >> Share

  402. GASTALDELLI A, Repetto E, Guja C, Hardy E, et al
    Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Nov 6. doi: 10.1111/dom.13907.
    >> Share

  403. BLEVINS TC, Barve A, Raiter Y, Aubonnet P, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 1 Diabetes Mellitus: Results of the INSTRIDE 3 Phase 3 Switch Study.
    Diabetes Obes Metab. 2019 Nov 5. doi: 10.1111/dom.13904.
    >> Share

    October 2019
  404. AVGERINOS I, Michailidis T, Liakos A, Karagiannis T, et al
    Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Oct 21. doi: 10.1111/dom.13899.
    >> Share

  405. HANAIRE H, Franc S, Borot S, Penfornis A, et al
    Efficacy of Diabeloop closed-loop to improve glycaemic control in patients with type 1 diabetes exposed to copious dinners or to sustained physical exercise.
    Diabetes Obes Metab. 2019 Oct 16. doi: 10.1111/dom.13898.
    >> Share

  406. LANDGRAF W, Owens DR, Frier BM, Zhang M, et al
    Fasting C-peptide, a biomarker for hypoglycaemia risk in insulin-naive people with type 2 diabetes initiating basal insulin glargine 100 U/mL.
    Diabetes Obes Metab. 2019 Oct 13. doi: 10.1111/dom.13897.
    >> Share

  407. GHOUSE J, Isaksen JL, Skov MW, Lind B, et al
    Effect of diabetes duration on the relationship between glycaemic control and risk of death in older adults with type 2 diabetes.
    Diabetes Obes Metab. 2019 Oct 9. doi: 10.1111/dom.13891.
    >> Share

  408. DOUROS A, Dell'Aniello S, Yu OHY, Suissa S, et al
    Comparative cardiovascular and hypoglycemic safety of glimepiride in type 2 diabetes: A population-based cohort study.
    Diabetes Obes Metab. 2019 Oct 9. doi: 10.1111/dom.13893.
    >> Share

  409. ABERER F, Pferschy PN, Tripolt NJ, Sourij C, et al
    Hypoglycaemia leads to a delayed increase in platelet and coagulation activation markers in people with type 2 diabetes treated with metformin only: Results from a stepwise hypoglycaemic clamp study.
    Diabetes Obes Metab. 2019 Oct 8. doi: 10.1111/dom.13889.
    >> Share

  410. DING Y, Zhu X, Li X, Chen H, et al
    Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2019 Oct 6. doi: 10.1111/dom.13887.
    >> Share

  411. ZABALA A, Darsalia V, Holzmann MJ, Franzen S, et al
    Risk of first stroke in patients with type 2 diabetes and the relation to glycaemic control: a nationwide observational study.
    Diabetes Obes Metab. 2019 Oct 1. doi: 10.1111/dom.13885.
    >> Share

  412. PETRUSKI-IVLEVA N, Schneeweiss S, Eapen S, Rajan A, et al
    Fournier's gangrene in type-2 diabetic patients using second-line anti-diabetic medications.
    Diabetes Obes Metab. 2019 Oct 1. doi: 10.1111/dom.13886.
    >> Share

    September 2019
  413. JI L, Sun N, Zhang Y, Zhang L, et al
    Efficacy of metformin in preventing progression to diabetes in Chinese subjects with impaired glucose regulation: Protocol for a multicenter, open-label, randomized, controlled clinical study.
    Diabetes Obes Metab. 2019 Sep 12. doi: 10.1111/dom.13884.
    >> Share

  414. KWAK SH, Hwang YC, Won JC, Bae JC, et al
    Comparison of Gemigliptin and Dapagliflozin Effects on Glycemic Variability in Type 2 Diabetes: A Randomized, Open-Label, Active-Controlled, 12-Week Study (STABLE II Study).
    Diabetes Obes Metab. 2019 Sep 10. doi: 10.1111/dom.13882.
    >> Share

  415. GIUGLIANO D, Ceriello A, De Nicola L, Perrone-Filardi P, et al
    Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antihyperglycaemic drug matters?
    Diabetes Obes Metab. 2019 Sep 9. doi: 10.1111/dom.13881.
    >> Share

  416. KE C, Shah BR, Luk AO, Di Ruggiero E, et al
    Cardiovascular Outcomes Trials in Type 2 Diabetes: Time to Include Young Adults.
    Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13874.
    >> Share

  417. RADHOLM K, Zhou Z, Clemens K, Neal B, et al
    Effects of SGLT2 inhibitors in type 2 diabetes, comparing women to men.
    Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13876.
    >> Share

  418. SHAO SC, Chang KC, Chien RN, Lin SJ, et al
    Effects of Sodium Glucose Co-transporter 2 Inhibitors on Serum Alanine Aminotransferase Values in Type 2 Diabetes Patients: A Multi-Institutional Cohort Study.
    Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13875.
    >> Share

  419. CHO YM, Deerochanawong C, Seekaew S, Suraamornkul S, et al
    Efficacy and safety of gemigliptin as add-on therapy to insulin with or without metformin in patients with type 2 diabetes mellitus (ZEUS II study).
    Diabetes Obes Metab. 2019 Sep 3. doi: 10.1111/dom.13873.
    >> Share

  420. IDRIS I
    News and Views September 2019: American Diabetes Association (ADA) 79th scientific session Highlights.
    Diabetes Obes Metab. 2019;21:2183-2186.
    >> Share

    August 2019
  421. MEN P, Qu S, Luo W, Li C, et al
    Comparison of lixisenatide in combination with basal insulin versus other insulin regimens for the treatment of patients with type 2 diabetes mellitus inadequately controlled by basal insulin: systematic review, network meta-analysis and cost-effectiv
    Diabetes Obes Metab. 2019 Aug 30. doi: 10.1111/dom.13871.
    >> Share

  422. SHIELDS BM, Hattersley AT, Farmer AJ
    Identifying routine clinical predictors of non-adherence to second line therapies in Type 2 diabetes: a retrospective cohort analysis in a large primary care database.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13865.
    >> Share

  423. STEVENS JE, Buttfield M, Wu T, Hatzinikolas S, et al
    Effects of sitagliptin on gastric emptying of, and the glycaemic and blood pressure responses to, a carbohydrate meal in type 2 diabetes.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13864.
    >> Share

  424. LANGFORD BE, Evans M, Haskins-Coulter T, O'Connor ME, et al
    Systematic Literature Review and Network Meta-Analysis of SGLT Inhibitors versus Metformin as Add-On to Insulin in Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13863.
    >> Share

  425. SANSOME DJ, Xie C, Veedfald S, Horowitz M, et al
    Mechanism of glucose lowering by metformin in type 2 diabetes: role of bile acids.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13869.
    >> Share

  426. KHUNTI K, Chen H, Cid-Ruzafa J, Fenici P, et al
    Glycaemic Control in Patients with Type 2 Diabetes Initiating Second-Line Therapy: Results From the Global DISCOVER Study Programme.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13866.
    >> Share

  427. GUO C, Zhou Q, Zhang D, Qin P, et al
    Total sedentary behavior and TV viewing with risk of overweight/obesity, type 2 diabetes, and hypertension: a dose-response meta-analysis.
    Diabetes Obes Metab. 2019 Aug 29. doi: 10.1111/dom.13867.
    >> Share

  428. BALLY L, Herzig D, Ruan Y, Wilinska ME, et al
    Short-term fully closed-loop insulin delivery using faster insulin aspart compared to standard insulin aspart in type 2 diabetes.
    Diabetes Obes Metab. 2019 Aug 28. doi: 10.1111/dom.13861.
    >> Share

  429. NAGARAJ SB, Sidorenkov G, van Boven JFM, Denig P, et al
    Predicting Short-term and Long-term HbA1c Response after Insulin Initiation in Patients with Type 2 Diabetes Mellitus using Machine Learning.
    Diabetes Obes Metab. 2019 Aug 27. doi: 10.1111/dom.13860.
    >> Share

  430. WATADA H, Kaneko S, Komatsu M, Ross Agner B, et al
    Superior HbA1c control with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with </=50 units insulin degludec in Japanese subjects with type 2 diabetes in a phase 3, double-blind, randomised trial.
    Diabetes Obes Metab. 2019 Aug 18. doi: 10.1111/dom.13859.
    >> Share

  431. CHILTON RJ
    Effects of Sodium-Glucose Cotransporter-2 Inhibitors on the Cardiovascular and Renal Complications of Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13854.
    >> Share

  432. DEKKERS CCJ, Sjostrom CD, Greasley PJ, Cain V, et al
    Effects of the SGLT2 inhibitor dapagliflozin on estimated plasma volume in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13855.
    >> Share

  433. KAKU K, Araki E, Tanizawa Y, Ross Agner B, et al
    Superior efficacy with the fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin-naive Japanese subjects with type 2 diabetes in a phase 3, open-label, randomised trial.
    Diabetes Obes Metab. 2019 Aug 13. doi: 10.1111/dom.13856.
    >> Share

  434. GENTILELLA R, Sesti G, Vazquez L, Sapin H, et al
    Dulaglutide is an effective treatment for lowering HbA1c in patients with type 2 diabetes regardless of Body Mass Index.
    Diabetes Obes Metab. 2019 Aug 7. doi: 10.1111/dom.13853.
    >> Share

  435. NORHAMMAR A, Bodegard J, Nystrom T, Thuresson M, et al
    Dapagliflozin vs Non-SGLT-2i Treatment is Associated with Lower Hospital Care Costs in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study.
    Diabetes Obes Metab. 2019 Aug 5. doi: 10.1111/dom.13852.
    >> Share

  436. LIM S, Oh TJ, Dawson J, Sattar N, et al
    Diabetes drugs and stroke risk: intensive vs. conventional glucose-lowering strategies, and implications of recent cardiovascular outcome trials.
    Diabetes Obes Metab. 2019 Aug 5. doi: 10.1111/dom.13850.
    >> Share

  437. GIUGLIANO D, Maiorino MI, Bellastella G, Longo M, et al
    GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: an updated meta-analysis including the REWIND and PIONEER 6 trials.
    Diabetes Obes Metab. 2019 Aug 2. doi: 10.1111/dom.13847.
    >> Share

  438. KIETSIRIROJE N, Pearson S, Campbell M, Ariens RAS, et al
    Double diabetes: A distinct high-risk group?
    Diabetes Obes Metab. 2019 Aug 2. doi: 10.1111/dom.13848.
    >> Share

  439. DICEMBRINI I, Mannucci E, Monami M, Pala L, et al
    Impact of Technology on Glycemic Control in Type 2 Diabetes: A Meta-Analysis of Randomized Trials on Continuous Glucose Monitoring and Continuous Subcutaneous Insulin Infusion.
    Diabetes Obes Metab. 2019 Aug 1. doi: 10.1111/dom.13845.
    >> Share

    July 2019
  440. BAILEY CJ, Del Prato S, Wei C, Reyner D, et al
    Durability of Glycemic Control with Dapagliflozin, an SGLT2 Inhibitor, Compared with Saxagliptin, a DPP4 Inhibitor, in Patients with Inadequately Controlled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13841.
    >> Share

  441. WILMOT EG, Choudhary P, Leelarathna L, Baxter M, et al
    Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13842.
    >> Share

  442. GIORGINO F, Yu M, Haupt A, Milicevic Z, et al
    Effect of Once Weekly Dulaglutide versus Insulin Glargine in Patients with Type 2 Diabetes and Different Baseline Glycaemic Patterns: A Post-Hoc Analysis of the AWARD-2 Clinical Trial.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13844.
    >> Share

  443. MORIERI ML, Rigato M, Frison V, Simioni N, et al
    Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes. A retrospective multicenter comparative effectiveness study.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13840.
    >> Share

  444. SANTOS-LOZANO JM, Rada M, Lapetra J, Guinda A, et al
    Prevention of type 2 diabetes in prediabetic patients by using functional olive oil enriched in oleanolic acid: The prediabole study, a randomised controlled trial.
    Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13838.
    >> Share

  445. TURTON J, Brinkworth GD, Field R, Parker H, et al
    An evidence-based approach to developing low-carbohydrate diets for type 2 diabetes management: a systematic review of interventions and methods.
    Diabetes Obes Metab. 2019 Jul 26. doi: 10.1111/dom.13837.
    >> Share

  446. RENDELL MS
    COMMENTARY: SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA Protocol.
    Diabetes Obes Metab. 2019 Jul 23. doi: 10.1111/dom.13836.
    >> Share

  447. MOSER O, Eckstein ML, McCarthy O, Deere R, et al
    Performance of the Freestyle(R) Libre flash glucose monitoring (flash GM) system in people with type 1 diabetes: a secondary outcome analysis of a randomised crossover trial.
    Diabetes Obes Metab. 2019 Jul 23. doi: 10.1111/dom.13835.
    >> Share

  448. LEDESMA G, Umpierrez GE, Morley JE, Lewis-D'Agostino D, et al
    Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13829.
    >> Share

  449. LI P, Geng Z, Ladage VP, Wu J, et al
    Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetes.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13832.
    >> Share

  450. HALVORSEN YD, Walford GA, Massaro J, Aftring RP, et al
    A 96-Week Multinational Randomized Double-Blind Parallel-Group Clinical Trial Evaluating the Safety and Effectiveness of Bexagliflozin as a Monotherapy for Adults with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13833.
    >> Share

  451. NICOLUCCI A, Charbonnel B, Gomes MB, Khunti K, et al
    Treatment patterns and associated factors in 14 668 people with type 2 diabetes initiating a second-line therapy: results from the global DISCOVER study programme.
    Diabetes Obes Metab. 2019 Jul 12. doi: 10.1111/dom.13830.
    >> Share

  452. CHIRIACO M, Pateras K, Virdis A, Charakida M, et al
    Association Between Blood Pressure Variability, Cardiovascular Disease And Mortality In Type 2 Diabetes: A Systematic Review And Meta-Analysis.
    Diabetes Obes Metab. 2019 Jul 7. doi: 10.1111/dom.13828.
    >> Share

  453. BAKER C, Wason S, Banks P, Sawhney S, et al
    Dose-Dependent Glycometabolic Effects of Sotagliflozin on Type 1 Diabetes Over 12 Weeks: the inTandem4 Trial.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13825.
    >> Share

  454. DEEROCHANAWONG C, Pheng CS, Matawaran BJ, Sheu WH, et al
    Use of SGLT-2 inhibitors in patients with type 2 diabetes mellitus and multiple cardiovascular risk factors: an Asian perspective and expert recommendations.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13819.
    >> Share

  455. HOLLANDER PA, Kiljanski J, Spaepen E, Harris CJ, et al
    The Risk of Clinically Relevant Hypoglycaemia in Patients with Type 2 Diabetes Self-titrating Insulin Glargine U-100.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13822.
    >> Share

  456. KENG MJ, Tsiachristas A, Leal J, Gray A, et al
    Impact of achieving primary care targets in Type 2 diabetes on health outcomes and healthcare costs.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13821.
    >> Share

  457. MULDER S, Heerspink HJL, Darshi M, Kim JJ, et al
    The effects of dapagliflozin on urinary metabolites in patients with type 2 diabetes.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13823.
    >> Share

  458. PRATLEY RE, Kang J, Trautmann ME, Hompesch M, et al
    Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13824.
    >> Share

  459. LEGA IC, Bronskill SE, Campitelli MA, Guan J, et al
    Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infections: a population-based study of older women and men with diabetes.
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13820.
    >> Share

  460. BAILEY TS, Wu J, Zhou FL, Gupta MTech RA, et al
    Switching to insulin glargine 300 units/mL in real-world older type 2 diabetes patients (DELIVER 3).
    Diabetes Obes Metab. 2019 Jul 2. doi: 10.1111/dom.13818.
    >> Share

    June 2019
  461. JENDLE J, Birkenfeld AL, Polonsky WH, Silver R, et al
    Improved treatment satisfaction in patients with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials.
    Diabetes Obes Metab. 2019 Jun 19. doi: 10.1111/dom.13816.
    >> Share

  462. KHUNTI K, Ji L, Medina J, Surmont F, et al
    Type 2 diabetes treatment and outcomes worldwide: A short review of the DISCOVER study programme.
    Diabetes Obes Metab. 2019 Jun 19. doi: 10.1111/dom.13817.
    >> Share

  463. HOLLAND JA, Martin WP, Docherty NG, le Roux CW, et al
    The Impact of Intentional Weight Loss on Diabetic Kidney Dixg104 10 sease.
    Diabetes Obes Metab. 2019 Jun 17. doi: 10.1111/dom.13813.
    >> Share

  464. GOLDENBERG RM, Gilbert JD, Hramiak IM, Woo VC, et al
    SGLT inhibitors in type 1 diabetes: place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA Protocol.
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13811.
    >> Share

  465. SABATINE MS, Giugliano RP, Leiter LA
    Correctly Understanding the Diabetes Data in FOURIER.
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13812.
    >> Share

  466. JOHANSEN ML, Schou M, Rossignol P, Holm MR, et al
    Effect of the mineralocorticoid receptor antagonist eplerenone on liver fat and metabolism in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial (MIRAD trial).
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13809.
    >> Share

  467. MELMER A, Zuger T, Lewis DM, Leibrand S, et al
    Glycemic Control in Individuals with Type 1 Diabetes Using an Open Source Artificial Pancreas System (OpenAPS).
    Diabetes Obes Metab. 2019 Jun 10. doi: 10.1111/dom.13810.
    >> Share

  468. KAKU K, Isaka H, Sakatani T, Toyoshima J, et al
    Efficacy and safety of ipragliflozin add-on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double-blind, phase 3 trial.
    Diabetes Obes Metab. 2019 Jun 7. doi: 10.1111/dom.13807.
    >> Share

  469. FRANC S, Joubert M, Daoudi A, Fagour C, et al
    Efficacy of two telemonitoring systems to improve glycaemic control during basal insulin initiation in patients with type 2 diabetes: The TeleDiab-2 randomised controlled trial.
    Diabetes Obes Metab. 2019 Jun 7. doi: 10.1111/dom.13806.
    >> Share

  470. RIED-LARSEN M, Johansen MY, MacDonald CS, Hansen KB, et al
    Type 2 diabetes remission one year after an intensive lifestyle intervention: A secondary analysis of a randomized clinical trial.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13802.
    >> Share

  471. ARODA VR, Saugstrup T, Buse JB, Donsmark M, et al
    Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13804.
    >> Share

  472. MARTONO DP, Heerspink HJL, Hak E, Denig P, et al
    No significant effect of type 2 diabetes-related genetic risk scores on HbA1c levels after initiating metformin or sulfonylurea derivatives.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13803.
    >> Share

  473. MISHRIKY BM, Powell JR, Wittwer JA, Chu JX, et al
    Do GLP-1RA and SGLT-2i reduce cardiovascular events in black patients with type 2 diabetes? A systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Jun 5. doi: 10.1111/dom.13805.
    >> Share

  474. HALVORSEN YD, Lock JP, Zhou W, Zhu F, et al
    A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin to sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults.
    Diabetes Obes Metab. 2019 Jun 4. doi: 10.1111/dom.13801.
    >> Share

    May 2019
  475. HALS IK, Fleiner HF, Reimers N, Astor MC, et al
    Testing for optimal beta cell preserving treatment in Latent Autoimmune Diabetes in Adults (LADA). Results from a 21 month randomized trial.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13797.
    >> Share

  476. SULLIVAN SD, Nicholls CJ, Gupta MTech RA, Meron AA, et al
    Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: DELIVER Naive D real-world study.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13793.
    >> Share

  477. PACKER M
    Critical Role of the Epicardium in Mediating Cardiac Inflammation and Fibrosis in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13792.
    >> Share

  478. ROSENSTOCK J, Perl S, Johnsson E, Garcia-Sanchez R, et al
    Triple Therapy With Low-Dose Dapagliflozin Plus Saxagliptin Versus Dual Therapy With Each Monocomponent, All Added to Metformin, in Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13795.
    >> Share

  479. YASHIRO H, Hamagami K, Hiyoshi H, Sugama J, et al
    SCO-792, an enteropeptidase inhibitor, improves disease status of diabetes and obesity in mice.
    Diabetes Obes Metab. 2019 May 30. doi: 10.1111/dom.13799.
    >> Share

  480. DAVIES MJ, Russell-Jones D, Barber TM, Lavalle-Gonzalez FJ, et al
    Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial.
    Diabetes Obes Metab. 2019 May 24. doi: 10.1111/dom.13791.
    >> Share

  481. WEISMAN A, Tomlinson GA, Lipscombe LL, Perkins BA, et al
    Author's reply to 'The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause mortality in diabetes'.
    Diabetes Obes Metab. 2019 May 21. doi: 10.1111/dom.13789.
    >> Share

  482. ABTAHI S
    The role of long-term effects of allopurinol on cardiovascular outcomes and all-cause mortality in diabetes.
    Diabetes Obes Metab. 2019 May 21. doi: 10.1111/dom.13790.
    >> Share

  483. MADDALONI E, Coleman RL, Pozzilli P, Holman RR, et al
    Long-term Risk of Cardiovascular Disease in Individuals with Latent Autoimmune Diabetes of Adults (UKPDS nnn).
    Diabetes Obes Metab. 2019 May 17. doi: 10.1111/dom.13788.
    >> Share

  484. BAKER WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, et al
    Effectiveness and Safety of Rivaroxaban and Warfarin for Prevention of Major Adverse Cardiovascular or Limb Events in Nonvalvular Atrial Fibrillation Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 May 17. doi: 10.1111/dom.13787.
    >> Share

  485. GARRY EM, Buse JB, Gokhale M, Lund JL, et al
    Study Design Choices for Evaluating Comparative Safety of Diabetic Medications: An Evaluation of Pioglitazone and Bladder Cancer Risk Among Older US Adults with Type-2 Diabetes.
    Diabetes Obes Metab. 2019 May 14. doi: 10.1111/dom.13774.
    >> Share

  486. TORIMOTO K, Okada Y, Goshima Y, Tokutsu A, et al
    Addition of canagliflozin to insulin improves glycemic control and reduces insulin dose in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2019 May 10. doi: 10.1111/dom.13770.
    >> Share

  487. HAKIM O, Bello O, Bonadonna RC, Mohandas C, et al
    Ethnic differences in intrahepatic lipid and its association with hepatic insulin sensitivity and insulin clearance between men of Black and White ethnicity with early type 2 diabetes.
    Diabetes Obes Metab. 2019 May 10. doi: 10.1111/dom.13771.
    >> Share

  488. PFOHL M, Pscherer S, Fritsche A, Anderten H, et al
    Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL - a sub-analysis of the Titration and OPtimisation (TOP) registry.
    Diabetes Obes Metab. 2019 May 8. doi: 10.1111/dom.13768.
    >> Share

  489. PIEBER TR, Svehlikova E, Brunner M, Halberg IB, et al
    Fast-acting insulin aspart in subjects with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
    Diabetes Obes Metab. 2019 May 8. doi: 10.1111/dom.13767.
    >> Share

  490. SHARIF S, Groenwold RH, van der Graaf Y, Berkelmans GF, et al
    Mediation analysis of the relationship between type 2 diabetes and cardiovascular events and all-cause mortality: findings from the SMART-cohort.
    Diabetes Obes Metab. 2019 May 7. doi: 10.1111/dom.13759.
    >> Share

  491. ANHOLM C, Kumarathurai P, Samkani A, Pedersen LR, et al
    Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13761.
    >> Share

  492. FRIAS JP, Wynne AG, Matyjaszek-Matuszek B, Bartaskova D, et al
    Efficacy and Safety of an Expanded Dulaglutide Dose Range: A Phase 2, Placebo-controlled Trial in Patients with Type 2 Diabetes on Metformin.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13764.
    >> Share

  493. CHRISTENSEN RH, Hansen CS, von Scholten BJ, Jensen MT, et al
    Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13758.
    >> Share

  494. TIAN J, Jin, Qi B, Qiyou D, et al
    Evidence and Potential Mechanisms of Traditional Chinese Medicine for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13760.
    >> Share

  495. INOUE M, Lorenz M, Muto H, Wesch R, et al
    Effect of single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase 1 randomized trial.
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13757.
    >> Share

  496. ZHOU FL, Watada H, Tajima Y, Berthelot M, et al
    Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation between sglt2 inhibitors and dpp4 inhibitors using a supervised machine learning algorithm (profile study): A Retrospective analysis of a japa
    Diabetes Obes Metab. 2019 May 3. doi: 10.1111/dom.13753.
    >> Share

  497. BAILEY CJ
    FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later.
    Diabetes Obes Metab. 2019;21:1079-1080.
    >> Share

    April 2019
  498. KOSHIZAKA M, Ishikawa K, Ishibashi R, Maezawa Y, et al
    Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open-label, blinded-endpoint, randomised contro
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13750.
    >> Share

  499. PETTUS J, Gill J, Paranjape S, Stewart J, et al
    Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring.
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13751.
    >> Share

  500. XIA J, Song Y, Rawal S, Wu J, et al
    Vitamin D Status during Pregnancy and the Risk of Gestational Diabetes Mellitus: A Longitudinal Study in a Multiracial Cohort.
    Diabetes Obes Metab. 2019 Apr 17. doi: 10.1111/dom.13748.
    >> Share

  501. ADIELS M, Taskinen MR, Bjornson E, Andersson L, et al
    Role of apolipoprotein C-III overproduction in diabetic dyslipidemia.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13744.
    >> Share

  502. GIUGLIANO D, De Nicola L, Maiorino MI, Bellastella G, et al
    Type 2 diabetes and the kidney: insights from cardiovascular outcome trials.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13743.
    >> Share

  503. WITTBRODT E, Chamberlain D, Arnold SV, Tang F, et al
    Eligibility of patients with type 2 diabetes for SGLT-2 inhibitor cardiovascular outcomes trials: an assessment using the Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2019 Apr 10. doi: 10.1111/dom.13738.
    >> Share

  504. HALLBERG SJ, Dockter NE, Kushner JA, Athinarayanan SJ, et al
    Improving the Scientific Rigor of Nutritional Recommendations for Adults with Type 2 Diabetes: A Comprehensive Review of the American Diabetes Association Guidelines Recommended Eating Patterns.
    Diabetes Obes Metab. 2019 Apr 3. doi: 10.1111/dom.13736.
    >> Share

  505. TSUJIMOTO T, Kajio H
    No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes taking non-steroidal anti-inflammatory drugs.
    Diabetes Obes Metab. 2019 Apr 3. doi: 10.1111/dom.13737.
    >> Share

  506. PATORNO E, Gopalakrishnan C, Brodovicz KG, Meyers A, et al
    Cardiovascular safety of linagliptin compared to other oral glucose lowering agents in patients with type 2 diabetes: a sequential monitoring program in routine care.
    Diabetes Obes Metab. 2019 Apr 2. doi: 10.1111/dom.13735.
    >> Share

  507. SPANOPOULOS D, Okhai H, Zaccardi F, Tebboth A, et al
    Temporal variation of renal function in people with type 2 diabetes mellitus: a retrospective UK Clinical Practice Research Datalink cohort study.
    Diabetes Obes Metab. 2019 Apr 2. doi: 10.1111/dom.13734.
    >> Share

  508. SEIDU S, Topsever P, Hambling CE, Cos FX, et al
    Deintensification in older patients with type 2 diabetes: a systematic review of approaches, rates and outcomes.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13724.
    >> Share

  509. ARONSON R, Abitbol A, Tweden KS
    First Assessment of the Performance of an Implantable CGM System Through 180 Days in a Primarily Adolescent Population with Type I Diabetes.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13726.
    >> Share

  510. YANG W, Ma J, Yuan G, Li L, et al
    Determining the optimal fasting glucose target for patients with type 2 diabetes: results of the multicentre, open-label, randomized-controlled FPG GOAL trial.
    Diabetes Obes Metab. 2019 Apr 1. doi: 10.1111/dom.13733.
    >> Share

  511. DASH S, Leiter LA
    Residual cardiovascular risk among people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:28-38.
    >> Share

  512. BENGALURU JAYANNA M, Robinson JG
    The extent to which statins have improved cardiovascular outcomes: Lessons from randomized trials and observational studies of "real world" practice in people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:17-27.
    >> Share

  513. DIJK W, Cariou B
    Efficacy and safety of proprotein convertase subtilisin/kexin 9 inhibitors in people with diabetes and dyslipidaemia.
    Diabetes Obes Metab. 2019;21 Suppl 1:39-51.
    >> Share


  514. New frontiers in cardiovascular risk reduction: people with diabetes and dyslipidaemia.
    Diabetes Obes Metab. 2019;21 Suppl 1:5.
    >> Share

  515. GONNA H, Ray KK
    The importance of dyslipidaemia in the pathogenesis of cardiovascular disease in people with diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 1:6-16.
    >> Share

  516. BOEDER S, Edelman SV
    Sodium-glucose co-transporter inhibitors as adjunctive treatment to insulin in type 1 diabetes: A review of randomized controlled trials.
    Diabetes Obes Metab. 2019;21 Suppl 2:62-77.
    >> Share

  517. BIESTER T, Kordonouri O, Danne T
    Beyond type 2 diabetes: sodium glucose co-transporter-inhibition in type 1 diabetes.
    Diabetes Obes Metab. 2019;21 Suppl 2:53-61.
    >> Share

    March 2019
  518. POLLOCK RF, Heller S, Pieber TR, Woo V, et al
    Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events - a Canadian setting (DEVOTE 9).
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13730.
    >> Share

  519. PETERS A, Piletic M, Ejstrud J, Salvesen-Sykes K, et al
    Baseline nocturnal glucose change: a predictor of the treatment effect of bolus intensification in insulin-treated type 2 diabetes.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13729.
    >> Share

  520. KLOECKER DE, Zaccardi F, Baldry E, Davies MJ, et al
    Efficacy of Low- and Very-Low-Energy Diets in people with Type 2 Diabetes Mellitus: A systematic review and meta-analysis of interventional studies.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13727.
    >> Share

  521. SCHMIDT S, Christensen MB, Serifovski N, Damm-Frydenberg C, et al
    Low versus High Carbohydrate Diet in Type 1 Diabetes: A 12-week randomized open-label crossover study.
    Diabetes Obes Metab. 2019 Mar 29. doi: 10.1111/dom.13725.
    >> Share

  522. KOSTEV K
    Longitudinal Changes in HbA1c following Therapy Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes in Germany.
    Diabetes Obes Metab. 2019 Mar 25. doi: 10.1111/dom.13707.
    >> Share

  523. FREEMANTLE N, Jourdan S
    Comment on "A comparative effectiveness study of degludec and insulin glargine 300 U/mL in insulin-naive patients with type 2 diabetes".
    Diabetes Obes Metab. 2019 Mar 22. doi: 10.1111/dom.13711.
    >> Share

  524. HELLER SR, DeVries JH, Wysham C, Hansen CT, et al
    Lower rates of hypoglycaemia in older people with type 2 diabetes when using insulin degludec versus insulin glargine U100: results from SWITCH 2.
    Diabetes Obes Metab. 2019 Mar 20. doi: 10.1111/dom.13708.
    >> Share

  525. YANG W, Ma J, Hong T, Liu M, et al
    Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: a phase 3, open-label, 2:1 randomized, treat-to-target trial.
    Diabetes Obes Metab. 2019 Mar 14. doi: 10.1111/dom.13703.
    >> Share

  526. VERMA S, Bain SC, Monk Fries T, Mazer CD, et al
    Duration of Diabetes and Cardiorenal Efficacy of Liraglutide and Semaglutide: A Post Hoc Analysis of the LEADER and SUSTAIN 6 Clinical Trials.
    Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13698.
    >> Share

  527. CHEN Y, Yuan Z, Lu J, Eliaschewitz FG, et al
    Randomised study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the China Population From the BERSON Clinical Trial.
    Diabetes Obes Metab. 2019 Mar 9. doi: 10.1111/dom.13700.
    >> Share

  528. RUSSELL-JONES D, Dauchy A, Delgado E, Dimitriadis G, et al
    Take Control: A Randomized Trial Evaluating the Efficacy and Safety of Self- Versus Physician-Managed Titration of Insulin Glargine 300 U/mL (Gla-300) in Patients with Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13697.
    >> Share

  529. PRATLEY RE, Emerson SS, Franek E, Gilbert MP, et al
    Cardiovascular safety and severe hypoglycaemia benefit of insulin degludec versus insulin glargine U100 in patients with type 2 diabetes aged 65 years or older: results from DEVOTE (DEVOTE 7).
    Diabetes Obes Metab. 2019 Mar 8. doi: 10.1111/dom.13699.
    >> Share

  530. KIM K, Unni S, Brixner DI, Thomas SM, et al
    Longitudinal Changes in HbA1c following Treatment Intensification after Inadequate Response to Two Oral Antidiabetic Agents in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Mar 7. doi: 10.1111/dom.13694.
    >> Share

  531. BAILEY TS, Zhou FL, Gupta RA, Preblick R, et al
    Glycemic goal attainment and hypoglycemia outcomes in type 2 diabetes patients initiating insulin glargine 300 units/mL or 100 units/mL: Real-world results from the DELIVER Naive cohort study.
    Diabetes Obes Metab. 2019 Mar 6. doi: 10.1111/dom.13693.
    >> Share

  532. DUNKLEY AJ, Fitzpatrick C, Gray LJ, Waheed G, et al
    Incidence and severity of hypoglycaemia in type 2 diabetes by treatment regimen: a UK multi-site 12-month prospective observational study.
    Diabetes Obes Metab. 2019 Mar 6. doi: 10.1111/dom.13690.
    >> Share

  533. LAN NS, Fegan PG, Yeap BB, Rankin JM, et al
    Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: act now to reduce it.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13689.
    >> Share

  534. ARAKI E, Yamashita S, Arai H, Yokote K, et al
    The Efficacy and Safety of Pemafibrate in Patients with Type 2 Diabetes and Elevated Triglyceride levels: 52-Week Data From The PROVIDE Study.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13686.
    >> Share

  535. JI L, Liu Y, Miao H, Xie Y, et al
    Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia.
    Diabetes Obes Metab. 2019 Mar 4. doi: 10.1111/dom.13681.
    >> Share

  536. DENNIS JM, Henley WE, McGovern AP, Farmer AJ, et al
    Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017.
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13687.
    >> Share

  537. MEIFFREN G, Herbrand T, Anastassiadis E, Klein O, et al
    Better glycemic control with BioChaperone Combo (BC Combo) than with insulin lispro Mix25 (LMix) or separate glargine & lispro (G+L) administrations after a test meal in subjects with type 2 diabetes (T2DM).
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13685.
    >> Share

  538. UNGER J, Allison DC, Carlton M, Lakkole K, et al
    Trial design and baseline data for LIRA-PRIME: a randomized trial investigating the efficacy of liraglutide in controlling glycemia in type 2 diabetes in a primary care setting.
    Diabetes Obes Metab. 2019 Mar 3. doi: 10.1111/dom.13682.
    >> Share

  539. LORENZATTI AJ, Eliaschewitz FG, Chen Y, Lu J, et al
    Randomised Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidaemia on Background Statin: Primary Results of the BERSON Clinical Trial.
    Diabetes Obes Metab. 2019 Mar 1. doi: 10.1111/dom.13680.
    >> Share

  540. KAKU K, Isaka H, Toyoshima J, Sakatani T, et al
    Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2019 Mar 1. doi: 10.1111/dom.13679.
    >> Share

    February 2019
  541. RUGGENENTI P, Trillini M, P Barlovic D, Cortinovis M, et al
    Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
    Diabetes Obes Metab. 2019 Feb 22. doi: 10.1111/dom.13639.
    >> Share

  542. VILSBOLL T, Blevins TC, Jodar E, Poulter N, et al
    Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin.
    Diabetes Obes Metab. 2019 Feb 20. doi: 10.1111/dom.13675.
    >> Share

  543. JACOBI SF, Khajavi N, Kleinau G, Teumer A, et al
    Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes.
    Diabetes Obes Metab. 2019 Feb 19. doi: 10.1111/dom.13634.
    >> Share

  544. MENEGHINI LF, Mauricio D, Orsi E, Lalic NM, et al
    The Diabetes Unmet Need with basal insulin Evaluation (DUNE) study in type 2 diabetes: Achieving HbA1c targets with basal insulin in a real-world setting.
    Diabetes Obes Metab. 2019 Feb 15. doi: 10.1111/dom.13673.
    >> Share

  545. JOHNSTON SS, Ammann EM, Kashyap SR, Stokes A, et al
    Body Mass Index and Insulin Use as Identifiers of High-Cost Patients with Type 2 Diabetes: A Retrospective Analysis of Electronic Health Records Linked to Insurance Claims Data.
    Diabetes Obes Metab. 2019 Feb 15. doi: 10.1111/dom.13671.
    >> Share

  546. TUTTLE KR, Lakshmanan MC, Rayner B, Zimmermann AG, et al
    Body Weight and eGFR during Dulaglutide Treatment in Type 2 Diabetes and Moderate-to-Severe Chronic Kidney Disease (AWARD-7).
    Diabetes Obes Metab. 2019 Feb 14. doi: 10.1111/dom.13668.
    >> Share

  547. LYTVYN Y, Bjornstad P, Lovshin JA, Singh SK, et al
    The Association Between Uric Acid, Renal Hemodynamics and Arterial Stiffness Over the Natural History of Type 1 Diabetes.
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13665.
    >> Share

  548. PHILIS-TSIMIKAS A, Billings LK, Busch R, Morales Portillo C, et al
    Superior Efficacy of Insulin Degludec/Liraglutide versus Insulin Glargine U100 as Add-on to Sodium-Glucose Co-Transporter-2 Inhibitor Therapy: a Randomized Clinical Trial in Patients with Uncontrolled Type 2 Diabetes.
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13666.
    >> Share

  549. LEE DH, Chun EJ, Oh TJ, Kim KM, et al
    Effect of Cilostazol, a Phosphodiesterase-3 Inhibitor, on Coronary Artery Stenosis and Plaque Characteristics in Patients with Type 2 Diabetes (ESCAPE Study).
    Diabetes Obes Metab. 2019 Feb 13. doi: 10.1111/dom.13667.
    >> Share

  550. PARKINSON J, Tang W, Astrand M, Melin J, et al
    Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2019 Feb 12. doi: 10.1111/dom.13664.
    >> Share

  551. CANIVELL S, Mata-Cases M, Real J, Franch-Nadal J, et al
    Glycemic Control after Treatment Intensification in Patients with Type 2 Diabetes Uncontrolled on Two or More Non-Insulin Antidiabetic Drugs in a Real-World Setting.
    Diabetes Obes Metab. 2019 Feb 12. doi: 10.1111/dom.13663.
    >> Share

  552. MEZQUITA RAYA P, Ampudia Blasco FJ, Hunt B, Martin V, et al
    Evaluating the Long-Term Cost-Effectiveness of ideglira for type 2 diabetes in spain based on Real-World clinical evidence.
    Diabetes Obes Metab. 2019 Feb 11. doi: 10.1111/dom.13660.
    >> Share

  553. WEISMAN A, Tomlinson GA, Lipscombe LL, Perkins BA, et al
    Association between allopurinol and cardiovascular outcomes and all-cause mortality in diabetes: A retrospective, population-based cohort study.
    Diabetes Obes Metab. 2019 Feb 8. doi: 10.1111/dom.13656.
    >> Share

  554. FUECHTENBUSCH M, Aberle J, Heitmann E, Nicolay C, et al
    Weight loss in patients with type 2 diabetes (T2D) mellitus receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: An AWARD-4 post-hoc analysis across baseline body mass index subgroups.
    Diabetes Obes Metab. 2019 Feb 8. doi: 10.1111/dom.13658.
    >> Share

  555. BELL DSH, Goncalves E
    Heart Failure in the diabetic patient - epidemiology, etiology, prognosis, therapy and the effect of glucose lowering medications.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13652.
    >> Share

  556. HE YL, Haynes W, Meyers CD, Amer A, et al
    The effects of licogliflozin, a dual SGLT1/2 inhibitor, on body weight in obese patients with or without diabetes.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13654.
    >> Share

  557. GARIANI K, Lebowitz D, Kressmann B, von Dach E, et al
    Oral Amoxicillin/Clavulanate for Treating Diabetic Foot Infections.
    Diabetes Obes Metab. 2019 Feb 5. doi: 10.1111/dom.13651.
    >> Share

  558. BOYE KS, Riddle MC, Gerstein HC, Mody R, et al
    Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials to the Overall Type 2 Diabetes Population in the United States.
    Diabetes Obes Metab. 2019 Feb 3. doi: 10.1111/dom.13649.
    >> Share

    January 2019
  559. TOYAMA T, Neuen BL, Jun M, Ohkuma T, et al
    Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2019 Jan 29. doi: 10.1111/dom.13648.
    >> Share

  560. MCGUIRE DK, Marx N, Johansen OE, Inzucchi SE, et al
    FDA Guidance on Antihyperglycemic Therapies for Type 2 Diabetes: One Decade Later.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13645.
    >> Share

  561. YU L, Li X, Zhang Z, Du P, et al
    Dimorphic autoantigenic and protective effects of Reg2 peptide in the treatment of diabetic beta-cell loss.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13644.
    >> Share

  562. LEITE NC, Viegas BB, Villela-Nogueira CA, Carlos FO, et al
    Efficacy of Diacerein in Reducing Liver Steatosis and Fibrosis in Patients with Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: a Randomized, Placebo-Controlled Trial.
    Diabetes Obes Metab. 2019 Jan 28. doi: 10.1111/dom.13643.
    >> Share

  563. CHARYTAN DM, Solomon SD, Ivanovich P, Remuzzi G, et al
    Metformin Use and Cardiovascular Events in Patients with Type 2 Diabetes and Chronic Kidney Disease.
    Diabetes Obes Metab. 2019 Jan 22. doi: 10.1111/dom.13642.
    >> Share

  564. ZOBEL EH, von Scholten BJ, Goldman B, Persson F, et al
    Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: individual effects of treatment.
    Diabetes Obes Metab. 2019 Jan 20. doi: 10.1111/dom.13638.
    >> Share

  565. JONES KL, Rigda RS, Buttfield MD, Hatzinikolas S, et al
    Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycemia in health and type 2 diabetes.
    Diabetes Obes Metab. 2019 Jan 9. doi: 10.1111/dom.13633.
    >> Share

  566. BORG MJ, Jones KL, Sun Z, Horowitz M, et al
    Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes.
    Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13632.
    >> Share

  567. GALLO S, Charbonnel B, Goldman A, Shi H, et al
    Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Diabetes Obes Metab. 2019 Jan 7. doi: 10.1111/dom.13631.
    >> Share

  568. NORHAMMAR A, Bodegard J, Nystrom T, Thuresson M, et al
    Dapagliflozin and Cardiovascular Mortality and Disease Outcomes in Type 2 Diabetes Patients Similar to the DECLARE-TIMI 58 Participants: A Nationwide Observational Study.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13627.
    >> Share

  569. GIUGLIANO D, Meier JJ, Esposito K
    Heart failure and type 2 diabetes: From CVOTs, with hope.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13629.
    >> Share

  570. FAN W, Song Y, Inzucchi SE, Sperling L, et al
    Composite Cardiovascular Risk Factor Target Achievement and its Predictors in US Adults with Diabetes: The Diabetes Collaborative Registry.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13625.
    >> Share

  571. FRIAS JP, Zimmer Z, Lam RLH, Lic GA, et al
    Double-blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin up-titration in treatment of patients with type 2 diabetes: the CompoSIT-M Study.
    Diabetes Obes Metab. 2019 Jan 4. doi: 10.1111/dom.13626.
    >> Share

    December 2018
  572. WANG C, Xiao Y, Wang J, Hou N, et al
    Dynamic Changes in Insulin and Glucagon During Disease Progression in Rhesus Monkeys with Obesity-Related Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Dec 21. doi: 10.1111/dom.13624.
    >> Share

  573. HEISE T, Meiffren G, Alluis B, Seroussi C, et al
    BioChaperone Lispro (BCLIS) vs faster aspart (FIA) and insulin aspart (ASP) in patients with type 1 diabetes on continuous subcutaneous insulin infusion: a randomized euglycemic clamp study.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13621.
    >> Share

  574. PAWASKAR M, Pinar Bilir S, Kowal S, Gonzalez C, et al
    Cost-effectiveness of intensification with SGLT2i in Type 2 Diabetes patients on metformin and sitagliptin compared to direct intensification with insulin in the United Kingdom.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13618.
    >> Share

  575. CHEN W, Zhou Y, Kong Z, Wang X, et al
    The Renoprotective Effects of SGLT2 Inhibitors versus Placebo in Patients with Type 2 Diabetes with or without Prevalent Kidney Disease: A Systematic Review and Meta-analysis.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13620.
    >> Share

  576. SINGH P, Pesavento TE, Washburn K, Walsh D, et al
    Largest single-center experience of dulaglutide for the management of diabetes mellitus in solid organ transplant.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13619.
    >> Share

  577. RETNAKARAN R, Ye C, Kramer CK
    Stability of Insulin and C-peptide Measurement with Long-term Frozen Storage of Serum: Implications for Diabetes Research Studies.
    Diabetes Obes Metab. 2018 Dec 18. doi: 10.1111/dom.13617.
    >> Share

  578. TIBALDI J, Hadley-Brown M, Liebl A, Haldrup S, et al
    A comparative effectiveness study of degludec and insulin glargine 300U/mL in insulin-naive patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13616.
    >> Share

  579. HOLMES RS, Crabtree E, McDonagh MS
    Comparative effectiveness and harms of long-acting insulins for Type 1 and Type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Dec 15. doi: 10.1111/dom.13614.
    >> Share

  580. ABDURRACHIM D, Teo XQ, Woo CC, Ong SY, et al
    Cardiac metabolic modulation upon low-carbohydrate low-protein ketogenic diet in diabetic rats studied in vivo using hyperpolarized (13) C pyruvate, butyrate, and acetoacetate probes.
    Diabetes Obes Metab. 2018 Dec 11. doi: 10.1111/dom.13608.
    >> Share

  581. BIRKELAND KI, Bodegard J, Norhammar A, Kuiper JG, et al
    How Representative are the Patients Included in the CV outcome Trials with SGLT2 Inhibitors of a General Type 2 Diabetes Population? A Large European Observational study.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13612.
    >> Share

  582. KLONOFF DC, Evans ML, Lane W, Kempe HP, et al
    A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13610.
    >> Share

  583. WU S, Gao L, Cipriani A, Huang Y, et al
    The effects of incretin-based therapies on beta-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13613.
    >> Share

  584. KUHADIYA ND, Prohaska B, Ghanim H, Dandona P, et al
    Addition of GLP-1RA therapy to Insulin in C-peptide Positive Patients With Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Dec 9. doi: 10.1111/dom.13609.
    >> Share

  585. HALAMA A, Kahal H, Bhagwat AM, Zierer J, et al
    The metabolic and proteomic signatures of hypoglycemia in type 2 diabetes.
    Diabetes Obes Metab. 2018 Dec 7. doi: 10.1111/dom.13602.
    >> Share

  586. OWENS DR, Landgraf W, Frier BM, Zhang M, et al
    Commencing insulin glargine 100 U/mL therapy in people with type 2 diabetes: Determinants of achievement of HbA1c goal <7.0.
    Diabetes Obes Metab. 2018 Dec 6. doi: 10.1111/dom.13607.
    >> Share

  587. MODY R, Huang Q, Yu M, Zhao R, et al
    Adherence, Persistence, Glycemic Control and Costs Among Patients with Type 2 Diabetes Initiating Dulaglutide Compared with Liraglutide or Exenatide QW at 12 Months Follow-Up in a US Real-World Setting.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13603.
    >> Share

  588. CHILTON RJ, Oliveros R, Gallegos KM, Pham S, et al
    PCSK9 inhibitors and diabetes: translational biology to clinical practice.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13600.
    >> Share

  589. WATSON LE, Phillips LK, Wu T, Bound MJ, et al
    A whey/guar "preload" improves postprandial glycaemia and HbA1c in type 2 diabetes - a 12-week, single-blind, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13604.
    >> Share

  590. WITTERT G, Atlantis E, Allan C, Bracken K, et al
    Testosterone therapy to prevent type 2 diabetes mellitus in at-risk men (T4DM): Design and implementation of a double-blind randomised controlled trial.
    Diabetes Obes Metab. 2018 Dec 5. doi: 10.1111/dom.13601.
    >> Share

    November 2018
  591. HANDELSMAN Y, Mathieu C, Del Prato S, Johnsson E, et al
    Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13594.
    >> Share

  592. WATADA H, Shiramoto M, Ueda S, Tang W, et al
    Pharmacokinetics and Pharmacodynamics of Dapagliflozin in Combination with Insulin in Japanese Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Nov 30. doi: 10.1111/dom.13593.
    >> Share

  593. MONAMI M, Sesti G, Mannucci E
    PCSK9 Inhibitor Therapy: A Systematic Review And Meta-Analysis of Metabolic And Cardiovascular Outcomes in Patients With Diabetes.
    Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13599.
    >> Share

  594. MOSER O, Pandis M, Aberer F, Kojzar H, et al
    A head-to-head comparison of personal and professional continuous glucose monitoring systems in people with type 1 diabetes: hypoglycaemia remains the weak spot.
    Diabetes Obes Metab. 2018 Nov 28. doi: 10.1111/dom.13598.
    >> Share

  595. BIESTER T, Nir J, Remus K, Farfel A, et al
    DREAM5: An open-label, randomized, cross-over study to evaluate the safety and efficacy of day and night closed-loop control using the MD-Logic automated insulin delivery system compared to sensor augmented pump therapy in patients with type 1 diabete
    Diabetes Obes Metab. 2018 Nov 26. doi: 10.1111/dom.13585.
    >> Share

  596. XIANG Y, Huang G, Zhu Y, Zuo X, et al
    Identification of autoimmune type 1 diabetes and multiple organ-specific autoantibodies in adult-onset non-insulin requiring diabetes in China: a population based multicenter national wide survey.
    Diabetes Obes Metab. 2018 Nov 24. doi: 10.1111/dom.13595.
    >> Share

  597. VELLANKI P, Rasouli N, Baldwin D, Alexanian S, et al
    Glycaemic Efficacy and Safety of Linagliptin compared to Basal-Bolus Insulin Regimen in Patients with Type 2 Diabetes Undergoing Non-Cardiac Surgery: A Multicenter Randomized Clinical Trial.
    Diabetes Obes Metab. 2018 Nov 20. doi: 10.1111/dom.13587.
    >> Share

  598. SOKOLOV V, Yakovleva T, Ueda S, Parkinson J, et al
    Urinary glucose excretion after dapagliflozin treatment: an exposure-response modeling comparison between Japanese and non-Japanese patients diagnosed with Type 1 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 Nov 19. doi: 10.1111/dom.13586.
    >> Share

  599. CUSI K, Bril F, Barb D, Polidori D, et al
    Effect of Canagliflozin Treatment on Hepatic Triglyceride Content and Glucose Metabolism in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13584.
    >> Share

  600. JENSEN J, Schou M, Kistorp C, Faber J, et al
    Prevalence of heart failure and diagnostic value of MR-proANP in outpatients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Nov 16. doi: 10.1111/dom.13583.
    >> Share

  601. BARER Y, Cohen O, Cukierman-Yaffe T
    The effect of glycemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Nov 13. doi: 10.1111/dom.13581.
    >> Share

  602. BONADONNA RC, Yale JF, Brulle-Wohlhueter C, Boelle-Le Corfec E, et al
    Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
    Diabetes Obes Metab. 2018 Nov 9. doi: 10.1111/dom.13578.
    >> Share

  603. JADAWJI C, Crasto W, Gillies C, Kar D, et al
    Prevalence and progression of diabetic nephropathy in South Asians, White Europeans and Afro-Caribbeans with Type 2 diabetes; a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Nov 8. doi: 10.1111/dom.13569.
    >> Share

  604. VAN BRUGGEN FH, Luijendijk HJ
    What the diabetes data in FOURIER trial fail to show.
    Diabetes Obes Metab. 2018 Nov 8. doi: 10.1111/dom.13576.
    >> Share

  605. MASON SA, Rasmussen B, van Loon LJC, Salmon J, et al
    Ascorbic acid supplementation improves postprandial glycaemic control and blood pressure in people with type 2 diabetes: Findings of a randomized cross-over trial.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13571.
    >> Share

  606. WOO V, Bell A, Clement M, Noronha L, et al
    CANadian CAnagliflozin Registry: Effectiveness and Safety of Canagliflozin in the treatment of Type 2 diabetes mellitus in Canadian Clinical Practice.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13573.
    >> Share

  607. ITOH H, Komuro I, Takeuchi M, Akasaka T, et al
    Achieving LDL-C target levels less than 70 mg/dL may provide extra cardiovascular protection in high-risk patients: exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients With Hypercholesterolemia and Diabetic Retinopathy St
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13575.
    >> Share

  608. ROUSSEL R, Duran Garcia S, Zhang Y, Shah S, et al
    Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Diabetes Obes Metab. 2018 Nov 4. doi: 10.1111/dom.13574.
    >> Share

    October 2018
  609. BORG MJ, Bound M, Grivell J, Sun Z, et al
    Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
    Diabetes Obes Metab. 2018 Oct 28. doi: 10.1111/dom.13567.
    >> Share

  610. DAVIS TME, Bruce DG, Finn J, Curtis BH, et al
    Temporal changes in the incidence and predictors of severe hypoglycaemia in type 2 diabetes: The Fremantle Diabetes Study.
    Diabetes Obes Metab. 2018 Oct 28. doi: 10.1111/dom.13568.
    >> Share

  611. KIM Y, Kang ES, Jang HC, Kim DJ, et al
    Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Diabetes Obes Metab. 2018 Oct 26. doi: 10.1111/dom.13566.
    >> Share

  612. DEVRIES JH, Bailey TS, Bhargava A, Gerety G, et al
    Day-to-day Fasting Self-monitored Blood Glucose Variability is Associated with Risk of Hypoglycaemia in Insulin-Treated Patients with Type 1 and Type 2 Diabetes: A Post Hoc Analysis of the SWITCH Trials.
    Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13565.
    >> Share

  613. VILJOEN A, Hoxer CS, Johansen P, Malkin S, et al
    Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly semaglutide versus dulaglutide for the treatment of type 2 diabetes mellitus in the UK.
    Diabetes Obes Metab. 2018 Oct 25. doi: 10.1111/dom.13564.
    >> Share

  614. HOVELMANN U, Braendholt Olsen M, Mouritzen U, Lamers D, et al
    Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 23. doi: 10.1111/dom.13562.
    >> Share

  615. ABERER F, Lichtenegger KM, Smajic E, Donsa K, et al
    GlucoTab guided insulin therapy using insulin glargine U300 enables glycaemic control with low risk of hypoglycaemia in hospitalised patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Oct 16. doi: 10.1111/dom.13559.
    >> Share

  616. AL-QAISSI A, Papageorgiou M, Javed Z, Heise T, et al
    Environmental effects of ambient temperature and relative humidity on insulin pharmacodynamics in adults with type 1 diabetes mellitus.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13555.
    >> Share

  617. BJORNSTAD P, Singh SK, Snell-Bergeon JK, Lovshin JA, et al
    The Relationships between Markers of Tubular Injury and Intrarenal Hemodynamic Function in Adults with and without Type 1 Diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13556.
    >> Share

  618. CHO KYG, Nakamura A, Omori K, Takase T, et al
    Effect of switching from pioglitazone to the SGLT2 inhibitor dapagliflozin on body weight and metabolism-related factors in patients with type-2 diabetes mellitus: An open-label, prospective, randomized, parallel-group comparison trial.
    Diabetes Obes Metab. 2018 Oct 12. doi: 10.1111/dom.13557.
    >> Share

  619. BAIN SC, Mosenzon O, Arechavaleta R, Bogdanski P, et al
    Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial.
    Diabetes Obes Metab. 2018 Oct 4. doi: 10.1111/dom.13553.
    >> Share

  620. GARCIA-FINANA M, Hughes DM, Cheyne CP, Broadbent DM, et al
    Personalized risk-based screening for diabetic retinopathy: a multivariate approach vs. the use of stratification rules.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13552.
    >> Share

  621. MAGALHAES JP, Judice PB, Ribeiro R, Andrade R, et al
    Effectiveness of high intensity interval training combined with resistance training vs. continuous moderate intensity training combined with resistance training in patients with type 2 diabetes - 1 year randomized controlled trial.
    Diabetes Obes Metab. 2018 Oct 3. doi: 10.1111/dom.13551.
    >> Share

  622. PEARCE I, Simo R, Lovestam-Adrian M, Wong DT, et al
    Association between diabetic eye disease and other complications of diabetes: implications for care. A systematic review.
    Diabetes Obes Metab. 2018 Oct 2. doi: 10.1111/dom.13550.
    >> Share

  623. MULDER S, Hamidi H, Kretzler M, Ju W, et al
    An integrative systems biology approach for precision medicine in diabetic kidney disease.
    Diabetes Obes Metab. 2018;20 Suppl 3:6-13.
    >> Share

  624. DE VRIES JK, Levin A, Loud F, Adler A, et al
    Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives.
    Diabetes Obes Metab. 2018;20 Suppl 3:24-29.
    >> Share

  625. MOL PGM, Thompson A, Heerspink HJL, Leufkens HGM, et al
    Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations.
    Diabetes Obes Metab. 2018;20 Suppl 3:19-23.
    >> Share

  626. HEERSPINK HJL, de Zeeuw D
    Treating diabetic complications; from large randomized clinical trials to precision medicine.
    Diabetes Obes Metab. 2018;20 Suppl 3:3-5.
    >> Share

  627. HEERSPINK HJL, List J, Perkovic V
    New clinical trial designs for establishing drug efficacy and safety in a precision medicine era.
    Diabetes Obes Metab. 2018;20 Suppl 3:14-18.
    >> Share

    September 2018
  628. AL-QAISSI A, Papageorgiou M, Deshmukh H, Madden LA, et al
    The effects of acute insulin-induced hypoglycaemia on endothelial microparticles in adults with and without type 2 diabetes.
    Diabetes Obes Metab. 2018 Sep 28. doi: 10.1111/dom.13548.
    >> Share

  629. NAUCK MA, Buse JB, Mann JFE, Pocock S, et al
    Health-related quality of life in people with type 2 diabetes participating in the LEADER trial.
    Diabetes Obes Metab. 2018 Sep 27. doi: 10.1111/dom.13547.
    >> Share

  630. BUSE JB, Carlson AL, Komatsu M, Mosenzon O, et al
    Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: efficacy and safety from a randomized double-blind trial.
    Diabetes Obes Metab. 2018 Sep 26. doi: 10.1111/dom.13545.
    >> Share

  631. LIAKOS A, Lambadiari V, Bargiota A, Kitsios K, et al
    Effect of liraglutide on ambulatory blood pressure in hypertensive patients with type 2 diabetes: randomized, double blind, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Sep 22. doi: 10.1111/dom.13541.
    >> Share

  632. BAIN SC, Klufas MA, Ho A, Matthews DR, et al
    Worsening diabetic retinopathy with rapid improvement in systemic glucose control: a review.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13538.
    >> Share

  633. SEUFERT J, Fritsche A, Pscherer S, Anderten H, et al
    Titration and optimization trial for the initiation of insulin glargine 100 U/mL in inadequately controlled type-2 diabetes patients on oral antidiabetic drugs.
    Diabetes Obes Metab. 2018 Sep 18. doi: 10.1111/dom.13535.
    >> Share

  634. ABDURRACHIM D, Teo XQ, Woo CC, Chan WX, et al
    Empagliflozin lowers myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized (13) C magnetic resonance spectroscopy study.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13536.
    >> Share

  635. NICHOLS GA, Philip S, Reynolds K, Granowitz CB, et al
    Increased Residual Cardiovascular Risk in Patients with Diabetes and High vs. Normal Triglycerides Despite Statin-Controlled LDL Cholesterol.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13537.
    >> Share

  636. MOSER O, Eckstein ML, Mueller A, Birnbaumer P, et al
    Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: a randomised cross-over trial.
    Diabetes Obes Metab. 2018 Sep 17. doi: 10.1111/dom.13534.
    >> Share

  637. KUO S, Yang CT, Wu JS, Ou HT, et al
    Effects of intensifying triple oral antidiabetic drug therapy by initiating insulin versus enhancing oral antidiabetic drug therapy on clinical outcomes in patients with type 2 diabetes: a nationwide population-based, propensity score-matched cohort s
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13525.
    >> Share

  638. SINGH RG, Nguyen NN, DeSouza SV, Pendharkar SA, et al
    Comprehensive analysis of body composition and insulin traits associated with intra-pancreatic fat deposition in health and new-onset prediabetes/diabetes after acute pancreatitis.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13523.
    >> Share

  639. YOSHIKAWA F, Kumashiro N, Shigiyama F, Uchino H, et al
    Efficacy of Intermittent Empagliflozin Supplementation on Dietary Self-Management and Glycemic Control in Patients With Poorly Controlled Type 2 Diabetes: A 24-Week Randomized Controlled Trial.
    Diabetes Obes Metab. 2018 Sep 5. doi: 10.1111/dom.13524.
    >> Share

  640. SHIMIZU M, Suzuki K, Kato K, Jojima T, et al
    Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13520.
    >> Share

  641. YU M, Shankar RR, Zhang R, Zhang Y, et al
    Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with pre-mixed insulin.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13517.
    >> Share

  642. NATALI A, Nesti L, Venturi E, Shore AC, et al
    Metformin is the key factor for elevated plasma GDF-15 levels in type 2 diabetes: a nested, case-control study.
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13519.
    >> Share

  643. KHUNTI K, Seidu S, Davies MJ
    Should sodium glucose co-transporter 2 inhibitors be considered as first line oral therapy for people with type 2 diabetes?
    Diabetes Obes Metab. 2018 Sep 3. doi: 10.1111/dom.13518.
    >> Share

  644. IDRIS I
    News and Views for September 2018: Highlights from the American Diabetes Association Scientific meeting, June 2018.
    Diabetes Obes Metab. 2018;20:2321-2324.
    >> Share

  645. RIAHI Y, Israeli T, Cerasi E, Leibowitz G, et al
    Effects of proinsulin misfolding on beta-cell dynamics, differentiation and function in diabetes.
    Diabetes Obes Metab. 2018;20 Suppl 2:95-103.
    >> Share

  646. FOLLI F, La Rosa S, Finzi G, Davalli AM, et al
    Pancreatic islet of Langerhans' cytoarchitecture and ultrastructure in normal glucose tolerance and in type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018;20 Suppl 2:137-144.
    >> Share

  647. MESZAROS G, Pasquier A, Vivot K, Goginashvili A, et al
    Lysosomes in nutrient signalling: A focus on pancreatic beta-cells.
    Diabetes Obes Metab. 2018;20 Suppl 2:104-115.
    >> Share

  648. LIU M, Weiss MA, Arunagiri A, Yong J, et al
    Biosynthesis, structure, and folding of the insulin precursor protein.
    Diabetes Obes Metab. 2018;20 Suppl 2:28-50.
    >> Share

  649. NAPOLITANO T, Silvano S, Vieira A, Balaji S, et al
    Role of ghrelin in pancreatic development and function.
    Diabetes Obes Metab. 2018;20 Suppl 2:3-10.
    >> Share

  650. ESGUERRA JLS, Nagao M, Ofori JK, Wendt A, et al
    MicroRNAs in islet hormone secretion.
    Diabetes Obes Metab. 2018;20 Suppl 2:11-19.
    >> Share

  651. WEI FY, Tomizawa K
    tRNA modifications and islet function.
    Diabetes Obes Metab. 2018;20 Suppl 2:20-27.
    >> Share

  652. THOMAIDOU S, Zaldumbide A, Roep BO
    Islet stress, degradation and autoimmunity.
    Diabetes Obes Metab. 2018;20 Suppl 2:88-94.
    >> Share

  653. PETRENKO V, Philippe J, Dibner C
    Time zones of pancreatic islet metabolism.
    Diabetes Obes Metab. 2018;20 Suppl 2:116-126.
    >> Share

  654. ALVELOS MI, Juan-Mateu J, Colli ML, Turatsinze JV, et al
    When one becomes many-Alternative splicing in beta-cell function and failure.
    Diabetes Obes Metab. 2018;20 Suppl 2:77-87.
    >> Share

    August 2018
  655. BOLLI GB, Wysham C, Fisher M, Chevalier S, et al
    A post hoc pooled analysis to evaluate hypoglycaemia risk with insulin glargine 300 U/mL (Gla-300) versus 100 U/mL (Gla-100) over wider nocturnal windows in people with type 2 diabetes on a basal-only insulin regimen.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13515.
    >> Share

  656. GRANADOS A, Gebremariam A, Gidding SS, Terry JG, et al
    Association of Abdominal Muscle Composition with Prediabetes and Diabetes: The CARDIA Study.
    Diabetes Obes Metab. 2018 Aug 29. doi: 10.1111/dom.13513.
    >> Share

  657. YU E, Ruiz-Canela M, Razquin C, Guasch-Ferre M, et al
    Changes in Arginine are Inversely Associated with Type 2 Diabetes: A Case-Cohort Study in the PREDIMED Trial.
    Diabetes Obes Metab. 2018 Aug 26. doi: 10.1111/dom.13514.
    >> Share

  658. BELL DSH, Goncalves E
    Atrial fibrillation and type 2 diabetes: prevalence, etiology, pathophysiology and effect of anti-diabetic therapies.
    Diabetes Obes Metab. 2018 Aug 24. doi: 10.1111/dom.13512.
    >> Share

  659. RYAN PB, Rosenthal N
    Comment on Ryan, et al. Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 ob
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13509.
    >> Share

  660. ARNOLD SV, Seman L, Tang F, Peri-Okonny PA, et al
    Real-World Opportunity of Empagliflozin to Improve Blood Pressure Control in African Americans with Type 2 Diabetes: An NCDR(R) "Research-to-Practice" Project From the Diabetes Collaborative Registry (DCR).
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13510.
    >> Share

  661. ARNOLD SV, Yap J, Lam CSP, Tang F, et al
    Management of patients with diabetes and heart failure with reduced ejection fraction: an international comparison.
    Diabetes Obes Metab. 2018 Aug 23. doi: 10.1111/dom.13511.
    >> Share

  662. DORIS J, Millar SA, Idris I, O'Sullivan SE, et al
    Genetic Polymorphisms of the Endocannabinoid System in Obesity and Diabetes.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13504.
    >> Share

  663. GARIANI K, Lebowitz D, von Dach E, Kressmann B, et al
    Remission in Diabetic Foot Infections: Duration of Antibiotic Therapy and Other Possible Associated Factors.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13507.
    >> Share

  664. WANG W, Ruiz LN, Filippova E, Song KH, et al
    Efficacy and Safety of Once-weekly Dulaglutide Versus Insulin Glargine in Mainly Asian Patients with Type 2 Diabetes Mellitus on Metformin and/or a Sulfonylurea: a 52-week Open-label, Randomized Phase 3 Trial.
    Diabetes Obes Metab. 2018 Aug 21. doi: 10.1111/dom.13506.
    >> Share

  665. BLEVINS TC, Barve A, Sun B, Raiter Y, et al
    Efficacy and Safety of MYL-1501D Versus Insulin Glargine in Patients With Type 2 Diabetes After 24 Weeks: Results of the Phase 3 INSTRIDE 2 Study.
    Diabetes Obes Metab. 2018 Aug 15. doi: 10.1111/dom.13495.
    >> Share

  666. PARKER ED, Wittbrodt ET, McPheeters JT, Frias JP, et al
    Comparison of Healthcare Resource Utilization and Costs in Type 2 Diabetes Patients Initiating Dapagliflozin versus Sitagliptin.
    Diabetes Obes Metab. 2018 Aug 12. doi: 10.1111/dom.13502.
    >> Share

  667. KORSMO-HAUGEN HK, Brurberg KG, Mann J, Aas AM, et al
    Carbohydrate quantity in the dietary management of type 2 diabetes - a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Aug 11. doi: 10.1111/dom.13499.
    >> Share

  668. KAKU K, Haneda M, Tanaka Y, Lee G, et al
    Linagliptin as add-on to empagliflozin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a two-part, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 Aug 9. doi: 10.1111/dom.13496.
    >> Share

  669. CHEN HF, Ho CA, Li CY
    Risk of heart failure in type 2 diabetes population: Comparison with non-diabetes subjects with and without coronary heart diseases.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13493.
    >> Share

  670. BAILEY CJ, Marx N
    Cardiovascular protection in type 2 diabetes: insights from recent outcome trials.
    Diabetes Obes Metab. 2018 Aug 8. doi: 10.1111/dom.13492.
    >> Share

  671. CHRISTENSEN P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, et al
    Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW).
    Diabetes Obes Metab. 2018 Aug 7. doi: 10.1111/dom.13466.
    >> Share

  672. ELBAZ-GREENER G, Bloch O, Kumets I, Blatt A, et al
    Endogenous GLP-1 system response is impaired during St-elevation myocardial infarction in type 2 diabetes patients.
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13490.
    >> Share

  673. BAE JC, Min KW, Kim YH, Kim KA, et al
    Efficacy and safety of fixed-dose comBination therApy with gemigLiptin (50 mg) and rosuvAstatiN (20 mg) Compared with Each monotherapy in patients with type 2 diabetes and dyslipidaemia (BALANCE): A multicentre, randomized, double-blind, controlled, p
    Diabetes Obes Metab. 2018 Aug 6. doi: 10.1111/dom.13491.
    >> Share

  674. MATIKAINEN N, Soderlund S, Bjornson E, Pietilainen K, et al
    Liraglutide treatment improves postprandial lipid metabolism and cardiometabolic risk factors in humans with adequately controlled type 2 diabetes: A single-centre randomised controlled study.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13487.
    >> Share

  675. NEYMAN A, Nelson J, Tersey S, Mirmira RG, et al
    Persistent Elevations in Circulating INS DNA Among Subjects with Longstanding Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Aug 2. doi: 10.1111/dom.13489.
    >> Share

  676. OUCHI M, Oba K, Suganami H, Yoshida A, et al
    This is in reply to the Letter by Kahathuduwa et al. titled "Unaccounted for regression to the mean renders conclusion of article titled 'Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor Tofogliflozin' unsubstantiated".
    Diabetes Obes Metab. 2018;20:2041-2042.
    >> Share

  677. ELVERT R, Herling AW, Bossart M, Weiss T, et al
    Running on mixed fuel-dual agonistic approach of GLP-1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: A comparative study between mice and non-human primates.
    Diabetes Obes Metab. 2018;20:1836-1851.
    >> Share

  678. MORALES J, Assumpcao-Morales M
    The 2018 update of the American College of Physicians glycaemic management recommendations: An invitation to continued inertia?
    Diabetes Obes Metab. 2018;20:1809-1811.
    >> Share

    July 2018
  679. LIAN J, McGhee SM, So C, Chau J, et al
    Long-term cost-effectiveness of Patient Empowerment Programme for Type 2 Diabetes Mellitus in primary care.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13485.
    >> Share

  680. AVGERINOS I, Karagiannis T, Malandris K, Liakos A, et al
    Glucagon-like peptide 1 receptor agonists and microvascular outcomes in type 2 diabetes: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 Jul 29. doi: 10.1111/dom.13484.
    >> Share

  681. RENARD E, Tubiana-Rufi N, Bonnemaison-Gilbert E, Coutant R, et al
    Closed-Loop Driven by Control-to-Range Algorithm Outperforms Threshold-Low-Glucose-Suspend Insulin Delivery on Glucose Control Albeit not on Nocturnal Hypoglycemia in Pre-pubertal Patients with Type 1 Diabetes in Supervised Hotel Setting.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13482.
    >> Share

  682. MOTTALIB A, Tomah S, Hafida S, Elseaidy T, et al
    Intensive Multidisciplinary Weight Management in Patients with Type 1 Diabetes and Obesity: a 1-Year Retrospective Matched Cohort Study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13478.
    >> Share

  683. SCHMEDT N, Andersohn F, Walker J, Garbe E, et al
    Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: a nested case-control study.
    Diabetes Obes Metab. 2018 Jul 25. doi: 10.1111/dom.13480.
    >> Share

  684. TANG H, Yang K, Song Y, Han J, et al
    Meta-analysis of the association between sodium-glucose cotransporter 2 inhibitors and risk of skin cancer among patients with type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13474.
    >> Share

  685. KU EJ, Lee DH, Jeon HJ, Oh TK, et al
    Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: an observational study in clinical practice.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13476.
    >> Share

  686. DAWWAS GK, Smith SM, Park H
    Cardiovascular Outcomes of Sodium Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jul 23. doi: 10.1111/dom.13477.
    >> Share

  687. SCOTT R, Morgan J, Zimmer Z, Lam RLH, et al
    A Randomized Clinical Trial of the Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in Patients with Type 2 Diabetes Mellitus and Mild Renal Insufficiency: The CompoSIT-R Study.
    Diabetes Obes Metab. 2018 Jul 18. doi: 10.1111/dom.13473.
    >> Share

  688. BRUCE DG, Davis WA, Davis TM
    Glycaemic control and mortality in older people with type 2 diabetes: The Fremantle Diabetes Study Phase II.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13469.
    >> Share

  689. JAVIER ESCALADA F, Halimi S, Senior PA, Bonnemaire M, et al
    Glycemic control and hypoglycemia benefits with insulin glargine 300 U/mL (Gla-300) extend to people with type 2 diabetes and mild-to-moderate renal impairment.
    Diabetes Obes Metab. 2018 Jul 13. doi: 10.1111/dom.13470.
    >> Share

  690. IDZERDA NMA, Persson F, Pena MJ, Brenner BM, et al
    NT-proBNP predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
    Diabetes Obes Metab. 2018 Jul 10. doi: 10.1111/dom.13465.
    >> Share

  691. KADOWAKI T, Sarai N, Hirakawa T, Taki K, et al
    Persistence of oral antidiabetic treatment for type 2 diabetes characterized by drug class, patient characteristics, and severity of renal impairment: A Japanese database analysis.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13463.
    >> Share

  692. ROSENSTOCK J, Handelsman Y, Vidal J, Ampudia Blasco FJ, et al
    Propensity score-matched comparative analyses of simultaneously administered fixed-ratio iGlarLixi (LixiLan) vs sequential administration of insulin glargine and lixisenatide in uncontrolled type 2 diabetes.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13462.
    >> Share

  693. WANG JL, Dong YH, Ko WC, Chang CH, et al
    Thiazolidinediones and reduced risk of incident bacterial abscess in adults with type 2 diabetes: a population-based cohort study.
    Diabetes Obes Metab. 2018 Jul 4. doi: 10.1111/dom.13461.
    >> Share

  694. HARJUTSALO V, Thomas MC, Forsblom C, Groop PH, et al
    Risk of coronary artery disease and stroke according to sex and presence of diabetic nephropathy in type 1 diabetes.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13456.
    >> Share

  695. RIDDERSTRALE M, Rosenstock J, Andersen KR, Woerle HJ, et al
    Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13457.
    >> Share

  696. GUO L, Chen L, Chang B, Yang L, et al
    A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral
    Diabetes Obes Metab. 2018 Jul 2. doi: 10.1111/dom.13454.
    >> Share

    June 2018
  697. ZULLO AR, Hersey M, Lee Y, Sharmin S, et al
    Outcomes of "Diabetes-Friendly" versus "Diabetes-Unfriendly" Beta-blockers in Older Nursing Home Residents with Diabetes after Acute Myocardial Infarction.
    Diabetes Obes Metab. 2018 Jun 28. doi: 10.1111/dom.13451.
    >> Share

  698. MULLER-WIELAND D, Kellerer M, Cypryk K, Skripova D, et al
    Efficacy and Safety of Dapagliflozin or Dapagliflozin Plus Saxagliptin Versus Glimepiride as Add-on to Metformin in Patients With Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Jun 27. doi: 10.1111/dom.13437.
    >> Share

  699. FRIER BM, Landgraf W, Zhang M, Bolli GB, et al
    Hypoglycaemia risk in the first eight weeks of titration with insulin glargine 100 U/mL in previously insulin-naive people with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13450.
    >> Share

  700. SPILLER S, Bluher M, Hoffmann R
    Plasma levels of free fatty acids correlate with type 2 diabetes mellitus.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13449.
    >> Share

  701. SULLIVAN SD, Bailey TS, Roussel R, Zhou FL, et al
    Clinical outcomes in real-world patients with type 2 diabetes switching from first- to second-generation basal insulin analogues: Comparative effectiveness of insulin glargine 300 units/mL and insulin degludec in the DELIVER D+ cohort study.
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13345.
    >> Share

  702. RYAN PB, Buse JB, Schuemie MJ, DeFalco F, et al
    Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (O
    Diabetes Obes Metab. 2018 Jun 25. doi: 10.1111/dom.13424.
    >> Share

  703. WEIR DL, Abrahamowicz M, Beauchamp ME, Eurich DT, et al
    Acute vs Cumulative Benefits of Metformin use in Patients with Type 2 Diabetes and Heart Failure.
    Diabetes Obes Metab. 2018 Jun 23. doi: 10.1111/dom.13448.
    >> Share

  704. STEPHENSON JJ, Raval AD, Kern DM, Bae JP, et al
    Nonadherence to Basal Insulin Among Patients With Type 2 Diabetes in a US Managed Care Population: Results from a Patient Survey.
    Diabetes Obes Metab. 2018 Jun 21. doi: 10.1111/dom.13446.
    >> Share

  705. SUGIMOTO DH, Dex T, Stager W, Aroda VR, et al
    Efficacy of iGlarLixi, a fixed-ratio combination of insulin glargine and lixisenatide, in patients with type 2 diabetes stratified as high and low risk according to HEDIS measures.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13438.
    >> Share

  706. ALFREDSSON J, Green JB, Stevens SR, Reed SD, et al
    Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13377.
    >> Share

  707. MELMER A, Kempf P, Lunger L, Pieber TR, et al
    Short-term effects of dapagliflozin on insulin sensitivity, postprandial glucose excursion, and ketogenesis in type 1 diabetes - a randomized, placebo-controlled, double blind, cross-over pilot study.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13439.
    >> Share

  708. JAIKUMKAO K, Pongchaidecha A, Chueakula N, Thongnak LO, et al
    Dapagliflozin, a SGLT2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, ER stress, and apoptosis in pre-diabetic rats.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13441.
    >> Share

  709. ANDERSEN G, Meiffren G, Lamers D, DeVries JH, et al
    Ultra-rapid BioChaperone Lispro Improves post-prandial Blood Glucose Excursions versus Insulin Lispro in a 14-day crossover Treatment Study in Patients with Type 1 Diabetes.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13442.
    >> Share

  710. KAZIERAD DJ, Chidsey K, Somayaji VR, Bergman AJ, et al
    Efficacy and Safety of the Glucagon Receptor Antagonist PF-06291874: A 12-Week, Randomized, Dose-Response Study in Patients With Type 2 Diabetes Mellitus on Background Metformin Therapy.
    Diabetes Obes Metab. 2018 Jun 19. doi: 10.1111/dom.13440.
    >> Share

  711. YAN Z, Shyr ZA, Fortunato M, Welscher A, et al
    High Fat Diet induced Remission of Diabetes in a subset of KATP -GOF Insulin Secretory-Deficient mice.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13423.
    >> Share

  712. KORSATKO S, Jensen L, Brunner M, Sach-Friedl S, et al
    Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in subjects with type 2 diabetes: a randomised, placebo-controlled, double-blind, crossover trial.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13422.
    >> Share

  713. RABBONE I, Minuto N, Toni S, Lombardo F, et al
    Insulin pump breakdown and infusion set failure in Italian children with type 1 diabetes: 1-year prospective observational study with suggestions to minimize clinical impact.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13419.
    >> Share

  714. TSURUTANI Y, Nakai K, Inoue K, Kosuke A, et al
    Comparative study of ipragliflozin with sitagliptin on multiple metabolic changes in Japanese patients with type 2 diabetes: a multicenter, randomized, prospective, open-label, active-controlled study.
    Diabetes Obes Metab. 2018 Jun 12. doi: 10.1111/dom.13421.
    >> Share

  715. FIORETTO P, Del Prato S, Buse JB, Goldenberg R, et al
    Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes and Moderate Renal Impairment (Chronic Kidney Disease Stage 3A): The DERIVE Study.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13413.
    >> Share

  716. TERAUCHI Y, Riddle MC, Hirose T, Koyama M, et al
    Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use.
    Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414.
    >> Share

  717. EMANUEL AL, de Clercq NC, Koopen AM, van Poelgeest E, et al
    Iloprost infusion prevents the insulin-induced reduction in skeletal muscle microvascular blood volume but does not enhance peripheral glucose uptake in type 2 diabetic patients.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13410.
    >> Share

  718. NIMRI R, Dassau E, Segall T, Muller I, et al
    Adjusting insulin doses in patients with type 1 diabetes that use insulin pump and continuous glucose monitoring - Variations among countries and physicians.
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13408.
    >> Share

  719. FARR OM, Mantzoros CS
    Obese individuals with type 2 diabetes demonstrate decreased activation of the salience-related insula and increased activation of the emotion/salience-related amygdala to visual food cues compared to non-obese individuals with diabetes: a preliminary
    Diabetes Obes Metab. 2018 Jun 8. doi: 10.1111/dom.13403.
    >> Share

  720. REZNIK Y, Habteab A, Castaneda J, Shin J, et al
    Contribution of basal and postprandial hyperglycemia in type 2 diabetes patients treated by an intensified insulin regimen: impact of pump therapy in the OPT2MISE trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13398.
    >> Share

  721. HANS DEVRIES J, Desouza C, Bellary S, Unger J, et al
    Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13396.
    >> Share

  722. HAN KA, Chon S, Chung CH, Lim S, et al
    Efficacy and safety of ipragliflozin as an add-on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: a randomized controlled trial.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13394.
    >> Share

  723. KAKU K, Kuroda S, Ishida K, Umeda Y, et al
    Efficacy and safety of trelagliptin in combination with insulin therapy in Japanese patients with type 2 diabetes: results from a randomized, phase IV study.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13397.
    >> Share

  724. JALVING AC, Gant CM, Binnenmars SH, Soedamah-Muthu SS, et al
    Glycemic Control In The Diabetes And Lifestyle Cohort Twente - A Cross-Sectional Assessment Of Lifestyle And Pharmacological Management On Hba1c Target Achievement.
    Diabetes Obes Metab. 2018 Jun 4. doi: 10.1111/dom.13399.
    >> Share

  725. KREBS JD, Arahill J, Cresswell P, Weatherall M, et al
    The effect of additional mealtime insulin bolus using an insulin-to-protein ratio compared to to usual carbohydrate counting on postprandial glucose in those with Type 1 diabetes who usually follow a carbohydrate-restricted diet: a randomised cross-ov
    Diabetes Obes Metab. 2018 Jun 1. doi: 10.1111/dom.13392.
    >> Share

    May 2018
  726. GANDA OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, et al
    Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.
    Diabetes Obes Metab. 2018 May 26. doi: 10.1111/dom.13384.
    >> Share

  727. NORONHA JC, Braunstein CR, Glenn A, Khan TA, et al
    Effect of Small Doses of Fructose and Allulose on Postprandial Glucose Metabolism in Type 2 Diabetes: A Double-blind, Randomized, Controlled, Acute Feeding Equivalence Trial.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13374.
    >> Share

  728. DRUMMOND RS, Malkin S, Du Preez M, Lee XY, et al
    Management of type 2 diabetes with Fixed-Ratio combination insulin degludec/liraglutide (IDEGLIRA) versus Basal-Bolus therapy (INSULIN GLARGINE U100 PLUS INSULIN ASPART): A Short-Term Cost-Effectiveness analysis in the UK setting.
    Diabetes Obes Metab. 2018 May 24. doi: 10.1111/dom.13375.
    >> Share

  729. CAO B, Rosenblat JD, Brietzke E, Park C, et al
    Comparative Efficacy and Acceptability of Anti-Diabetic Agents for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and Network Meta-analysis.
    Diabetes Obes Metab. 2018 May 23. doi: 10.1111/dom.13373.
    >> Share

  730. KAWASAKI R, Konta T, Nishida K
    Lipid-lowering medication use is associated with decreased risk of diabetic retinopathy and its treatments in patients with type 2 diabetes: a real-world observational analysis of a health claims database.
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13372.
    >> Share

  731. BELL DSH, Goncalves E
    Should we still be utilizing warfarin in the type 2 diabetic patient?
    Diabetes Obes Metab. 2018 May 22. doi: 10.1111/dom.13371.
    >> Share

  732. LESLIE RD, Pozzilli P, Peters AL, Buzzetti R, et al
    Response to the comment on Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2,-4 and -5 Trials.
    Diabetes Obes Metab. 2018 May 20. doi: 10.1111/dom.13366.
    >> Share

  733. SUZUKI R, Eiki JI, Moritoyo T, Furihata K, et al
    Effect of Short Term Treatment with Sitagliptin or Glibenclamide on Daily Glucose Fluctuation in Drug-naive Japanese Patients with Type 2 Diabetes Mellitus.
    Diabetes Obes Metab. 2018 May 17. doi: 10.1111/dom.13364.
    >> Share

  734. KAWAMORI R, Haneda M, Suzaki K, Cheng G, et al
    Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13352.
    >> Share

  735. HOME PD, Lam RLH, Carofano WL, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13354.
    >> Share

  736. AHREN B, Atkin SL, Charpentier G, Warren ML, et al
    Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13353.
    >> Share

  737. SHIMADA A, Hanafusa T, Yasui A, Lee G, et al
    Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Diabetes Obes Metab. 2018 May 15. doi: 10.1111/dom.13351.
    >> Share

  738. HOLLANDER PA, Carofano WL, Lam RLH, Golm GT, et al
    Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 2 diabetes: a randomized, open-label clinical trial.
    Diabetes Obes Metab. 2018 May 14. doi: 10.1111/dom.13363.
    >> Share

  739. ANDREADIS P, Karagiannis T, Malandris K, Avgerinos I, et al
    Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13361.
    >> Share

  740. BAILEY CJ
    European Medicines Agency: approval of new glucose-lowering medicines for type 2 diabetes.
    Diabetes Obes Metab. 2018 May 13. doi: 10.1111/dom.13360.
    >> Share

  741. PETRI KCC, Ingwersen SH, Flint A, Zacho J, et al
    Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes.
    Diabetes Obes Metab. 2018 May 11. doi: 10.1111/dom.13358.
    >> Share

  742. CURTIN F, Bernard C, Levet S, Perron H, et al
    A new therapeutic approach for type 1 diabetes: rationale for GNbAC1 an anti-HERV-W-Env monoclonal antibody.
    Diabetes Obes Metab. 2018 May 10. doi: 10.1111/dom.13357.
    >> Share

  743. BLIND E, Janssen H, Dunder K, de Graeff PA, et al
    The European Medicines Agency's Approval of New Medicines for Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13349.
    >> Share

  744. FITZPATRICK C, Chatterjee S, Seidu S, Bodicoat DH, et al
    Association of hypoglycaemia and cardiac arrhythmia risk in patients with diabetes mellitus: A systematic review and meta-analysis.
    Diabetes Obes Metab. 2018 May 8. doi: 10.1111/dom.13348.
    >> Share

  745. CURTIS HJ, Dennis JM, Shields BM, Walker AJ, et al
    Time Trends and Geographical Variation in Prescribing of Drugs for Diabetes in England 1998-2017.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13346.
    >> Share

  746. MAIORINO MI, Chiodini P, Bellastella G, Scappaticcio L, et al
    Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Diabetes Obes Metab. 2018 May 7. doi: 10.1111/dom.13343.
    >> Share

  747. OVERBEEK J, Heintjes E, Huisman E, Tikkanen C, et al
    Clinical Effectiveness of Liraglutide versus Basal Insulin in a Real-world Setting: Evidence for Improved Glycaemic and Weight Control in Obese Patients with Type 2 Diabetes.
    Diabetes Obes Metab. 2018 May 3. doi: 10.1111/dom.13335.
    >> Share

  748. HUANG CJ, Wang WT, Sung SH, Chen CH, et al
    Blood Glucose Reduction by Diabetic Drugs with Minimal Hypoglycemia Risk for Cardiovascular Outcomes: Evidence from Meta-regression Analysis of Randomized Controlled Trials.
    Diabetes Obes Metab. 2018 May 2. doi: 10.1111/dom.13342.
    >> Share

    April 2018
  749. CHEN YH, Huang CN, Cho YM, Li P, et al
    Efficacy and safety of dulaglutide monotherapy compared to glimepiride in East Asian patients with type 2 diabetes in a multicenter, double-blind, randomized, parallel-arm, active comparator, phase 3 trial.
    Diabetes Obes Metab. 2018 Apr 30. doi: 10.1111/dom.13340.
    >> Share

  750. GOLDENBERG RM, Assimakopoulos P, Gilbert JD, Gottesman IS, et al
    A Practical Approach and Algorithm for Intensifying Beyond Basal Insulin in Type 2 Diabetes.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13337.
    >> Share

  751. ZHU XX, Zhu DL, Li XY, Li YL, et al
    Dorzagliatin (HMS5552), a Novel Dual Acting Glucokinase Activator, Improves Glycemic Control and Pancreatic beta-cell Function in Patients with Type 2 Diabetes: A 28-day Treatment Study Using Biomarker-Guided Patient Selection.
    Diabetes Obes Metab. 2018 Apr 29. doi: 10.1111/dom.13338.
    >> Share

  752. PANDEYA N, Huxley RR, Chung HF, Dobson AJ, et al
    Female reproductive history and risk of type 2 diabetes: a prospective analysis of 126,721 women.
    Diabetes Obes Metab. 2018 Apr 25. doi: 10.1111/dom.13336.
    >> Share

  753. WARREN M, Chaykin L, Trachtenbarg D, Nayak G, et al
    Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: pooled analysis of the SUSTAIN 1-5 trials.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13331.
    >> Share

  754. LIU DM, Mosialou I, Liu JM
    Bone: another potential target to treat, prevent and predict diabetes.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13330.
    >> Share

  755. COLLIER A, Connelly PJ, Hair M, Cameron L, et al
    Mortality risk is still higher in people with type 1 diabetes: a population-based cohort study (The Ayrshirre Diabetes fOllow-up Cohort (ADOC) study).
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13334.
    >> Share

  756. SIDORENKOV G, van Boven JFM, Hoekstra T, Nijpels G, et al
    HbA1c response after insulin initiation in patients with type 2 diabetes in real-life: identifying distinct subgroups.
    Diabetes Obes Metab. 2018 Apr 23. doi: 10.1111/dom.13332.
    >> Share

  757. OUT M, Top WMC, Lehert P, Schalkwijk CA, et al
    Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post hoc analysis of a randomised placebo-controlled trial.
    Diabetes Obes Metab. 2018 Apr 17. doi: 10.1111/dom.13327.